INVITATION TO SUBSCRIBE FOR UNITS IN PROSTATYPE GENOMICS AB

21 May–4 June 2025

This is a translation of the original version in Swedish for information purposes only.
In case of a discrepancy, the Swedish original will prevail.

Note that the unit rights may have an economic value. In order not to lose the value of the unit rights, the holder must either exercise the received unit rights and subscribe for units no later than 4 June 2025, or sell the received unit rights that are not intended to be exercised for subscription of units no later than 30 May 2025.

Please note that it is also possible to apply for subscription of units without unit rights. Please also note that shareholders with nominee-registered holdings subscribe for units through their respective nominee. The distribution of this prospectus and subscription of units is subject to restrictions in certain jurisdictions, see section 'Important information'.

The Swedish Financial Supervisory Authority approved this prospectus on 16 May 2025. The prospectus is valid for a period of 12 months from the date of approval, provided that it is supplemented with supplements when required under Article 23 of the Prospectus Regulation (EU) 2017/1129. The obligation to provide supplements to the prospectus in case of significant new factors, factual errors or material inaccuracies will not apply after the expiry of the validity of the prospectus.

Prostatype Genomics

THIS IS A TRANSLATION OF THE ORIGINAL VERSION IN SWEDISH FOR INFORMATION PURPOSES ONLY.
IN CASE OF A DISCREPANCY, THE SWEDISH ORIGINAL WILL PREVAIL.

IMPORTANT INFORMATION TO INVESTORS

In this EU Growth Prospectus, the '**Company**' or '**Prostatype Genomics**' refers to Prostatype Genomics AB with corporate identity number 556726-0285. The prospectus has been prepared in connection with the Company's current issue of shares with preferential rights for existing shareholders (the '**Offering**' or the '**Rights Issue**').

The Prospectus has been prepared as an EU growth prospectus in accordance with Article 15 of Regulation (EU) 2017/1129 of the European Parliament and of the Council (the '**Prospectus Regulation**'). The Prospectus has been approved and registered by the Swedish Financial Supervisory Authority as the competent authority under the Prospectus Regulation. The FIN-FSA approves this prospectus only to the extent that it fulfils the requirements of completeness, comprehensibility and consistency set out in the Prospectus Regulation. The approval should not be considered as an endorsement of the Company or of the quality of the securities referred to in this prospectus and does not imply that the FIN-FSA guarantees the accuracy or completeness of the information contained in the prospectus. Each investor is encouraged to make its own judgement as to whether it is appropriate to participate in the Rights Issue. The prospectus is governed by Swedish law. Disputes arising from the prospectus and related legal matters shall be settled exclusively by Swedish courts, whereby the Stockholm District Court shall be the court of first instance. The prospectus is available on the Company's website www.prostatypegenomics.com and the Swedish Financial Supervisory Authority's website www.fi.se.

The Offer is not being made to the public in any jurisdiction other than Sweden. No unit rights, paid subscription units ('**BTU**'), shares or warrants in Prostatype Genomics AB have been or will be registered under the U.S. Securities Act of 1933, as amended, or the securities laws of any state or other jurisdiction of the United States, and no securities may be offered, subscribed for, sold or transferred, directly or indirectly, in or into the United States, except pursuant to applicable exemptions from the registration requirements of the U.S. Securities Act (as amended). Further, the Offer is not being made to persons resident in Australia, Japan, Canada, New Zealand, South Africa, South Korea, Russia, Belarus, Hong Kong, Switzerland, Singapore or any other jurisdiction where participation would require additional prospectuses, registration or other measures beyond those required by Swedish law. The Prospectus and/or other documents related to the Offering may not be distributed in or into any jurisdiction where the Offering requires measures as set out above or would be contrary to applicable law. No action has been taken or will be taken in any jurisdiction other than Sweden that would authorise the offering of securities to the public, or permit the possession, distribution of the Prospectus or any other material relating to the Company or its securities in such jurisdiction. Application for subscription of shares in the Company in violation of the above restrictions may be deemed invalid.

Persons receiving the prospectus are required by the Company to inform themselves about, and to observe, all such restrictions. The Company accepts no legal responsibility for any breach of any such restriction by any person, whether the breach is committed by a prospective investor or anyone else. Action in violation of the restrictions may constitute a violation of applicable securities laws. Within the European Economic Area ('**EEA**'), no public offer of shares is being made in Member States other than Sweden. In other Member States of the EEA where the Prospectus Regulation applies, an offer of shares may only be made in accordance with exemptions in the Prospectus Regulation and any implementing measures.

An investment in securities involves risks, see section 'Risk Factors'. In making an investment decision, investors must rely on their own judgement of Prostatype Genomics and the Offering under this prospectus, including the facts and risks involved. Prior to making an investment decision, potential investors should seek their own professional advice and carefully evaluate and consider the investment decision. Investors should rely only on the information contained in this prospectus and any supplements to this prospectus. No person has been authorised to give any information or to make any representations other than those contained in this prospectus and, if given or made, such information or representations must not be relied upon as having been authorised by Prostatype Genomics and the Company accepts no responsibility for such information or representations. Neither the publication of this prospectus nor any transaction entered into in connection herewith shall under any circumstances be deemed to imply that the information contained in this prospectus is correct and valid at any time other than as of the date of publication of this prospectus or that there has been no change in the business of Prostatype Genomics after such date.

Advisors and issuing agent

In connection with the Offering, Gemstone Capital A/S ('**Gemstone**') and Navia Corporate Finance AB ('**Navia**') are acting as financial advisors, Nordic Issuing AB ('**Nordic Issuing**') as issuing agent and Advokatfirman Lindahl KB ('**Lindahl**') as legal advisor to Prostaype Genomics. The board of directors of Prostaype Genomics is responsible for the contents of this prospectus, whereby Gemstone, Navia and Lindahl disclaim all liability in relation to shareholders in the Company and in relation to other direct or indirect consequences resulting from investment decisions or other decisions based in whole or in part on the information in the prospectus.

Forward-looking statements and industry and market information

The Prospectus contains certain forward-looking statements that reflect the Company's current view of future events and financial and operational development. Such forward-looking statements are subject to known and unknown risks and circumstances beyond the Company's control. In light of the risks, uncertainties and assumptions associated with forward-looking statements, it is possible that future events mentioned in this prospectus will not occur. Forward-looking statements are all statements in this prospectus that do not relate to historical or current facts or circumstances and those that relate to the future. The forward-looking statements are based on current estimates and assumptions, which are made to the best of the Company's knowledge. Forward-looking statements are made in most sections of this prospectus and can be identified by the use of words such as 'in the opinion of the Board of Directors', 'may' and 'are expected' or variations of such words or similar expressions which identify a statement as forward-looking.

The section 'Risk Factors' contains a description of some, but not all, factors that could cause the Company's future results and performance to differ materially from those expressed or implied in any forward-looking statement. The forward-looking statements speak only as of the date of this prospectus and the Company does not thereafter assume any responsibility to publish updated forward-looking statements or other information in this prospectus based on new information, future events, etc.

The prospectus contains industry and market information related to the Company's operations and the market in which Prostatype Genomics operates. Unless otherwise stated, such information is based on the Company's analysis of several different sources. Potential investors should be aware that financial information, market information and forecasts and estimates of market information contained in the Prospectus are not necessarily reliable indicators of the Company's future performance.

Nasdaq First North Growth Market

Nasdaq First North Growth Market is a registered SME marketplace for growth companies, in accordance with the Markets in Financial Instruments Directive (EU2014/65) (the '**Directive**') as implemented in the national legislation of Denmark, Finland and Sweden. The marketplace is part of the Nasdaq Group. Issuers on Nasdaq First North Growth Market are not subject to the regulation applicable to issuers whose shares are listed on a regulated market, as the term is defined in Article 4.1.21 of the Directive and Chapter 1, section 4b of the Act (2007 5287) on the Financial Markets. Instead, they are subject to a less extensive regulatory framework that is adapted for smaller growth companies. The risks associated with an investment in an issuer listed on Nasdaq First North Growth Market may therefore be higher than for an investment in an issuer listed on a regulated market. All issuers with shares listed for trading on Nasdaq First North Growth Market must have a Certified Adviser who monitors compliance with the regulations for the marketplace. DNB Carnegie ('**Carnegie**') is the Company's Certified Adviser.

THIS IS A TRANSLATION OF THE ORIGINAL VERSION IN SWEDISH FOR INFORMATION PURPOSES ONLY.
IN CASE OF A DISCREPANCY, THE SWEDISH ORIGINAL WILL PREVAIL.

TABLE OF CONTENTS

DOCUMENTS INCORPORATED BY REFERENCE 4
SUMMARY 5
RESPONSIBLE PERSONS, INFORMATION FROM THIRD PARTIES, AND APPROVAL BY COMPETENT AUTHORITIES 11
BACKGROUND AND MOTIVE 12
BUSINESS- AND MARKET OVERVIEW 15
WORKING CAPITAL STATEMENT 26
RISK FACTORS 27
TERMS FOR THE SECURITIES 32
TERMS AND CONDITIONS 35
BOARD OF DIRECTORS AND MANAGEMENT 41
FINANCIAL INFORMATION AND KEY FIGURES 45
AVAILABLE DOCUMENTS 52

DOCUMENTS INCORPORATED BY REFERENCE

Investors should note that the information incorporated in the prospectus by reference should be read as part of the prospectus. The information set out below, as part of the following documents, is deemed to be incorporated into the prospectus by reference. Copies of the prospectus and the documents incorporated by reference may be obtained from Prostatype Genomics in electronic format via the Company's website, www.prostatypegenomics.com, or obtained by the Company in paper format at Prostaype Genomics' office with address Augustendalsvägen 20, 131 52 Nacka Strand. The parts of the document that are not incorporated are either not relevant to investors or the information is reproduced elsewhere in the prospectus.

Please note that the information on Prostatype Genomics' website, or other websites to which reference is made, is not included in the prospectus unless such information is incorporated into the prospectus by reference. The information on the Company's website, or websites referred to in the prospectus, has not been reviewed or approved by the Swedish Financial Supervisory Authority.

THE COMPANY'S ANNUAL REPORT FOR THE FISCAL YEAR 2024-01-01 – 2024-12-31

	Page
Income statement	19
Balance sheet	20-21
Cashflow statement	22
Company statement of changes in equity	23-24
Notes	25-36
Auditor's report	40-42

Prostatype Genomics' annual report for the financial year 2024 is available at the following link: ***Annual report 2024***

THE COMPANY'S ANNUAL REPORT FOR THE FISCAL YEAR 2023-01-01 – 2023-12-31

	Page
Income statement	23
Balance sheet	24-25
Cashflow statement	26
Company statement of changes in equity	27-28
Notes	29-40
Auditor's report	44-46

Prostatype Genomics' annual report for the financial year 2023 is available at the following link: ***Annual report 2023***

The annual reports for 2023 and 2024 have been audited by the Company's auditor. Other than these annual reports, no information in this prospectus has been subject to review by the auditor.

THIS IS A TRANSLATION OF THE ORIGINAL VERSION IN SWEDISH FOR INFORMATION PURPOSES ONLY.
IN CASE OF A DISCREPANCY, THE SWEDISH ORIGINAL WILL PREVAIL.

SUMMARY

SECTION 1 – INTRODUCTION

1.1	**The securities name and ISIN-code**	The Offering consists of units in Prostatype Genomics AB. The shares in Prostatype Genomics have the ticker 'PROGEN' and the ISIN code SE0023261532, the unit rights have the ISIN code SE0024990071 and the BTUs have the ISIN code SE0024990089.
1.2	**Identity, LEI-code and contact details for the issuer**	The Company's name is Prostatype Genomics AB, with organisation number 556726-0285. The Company's identification code (LEI) is 549300JO6MPCGPVHVU91. The Company's trading name is PROGEN. Representatives of the Company can be reached by telephone at +46 70-545 05 20 and by e-mail at anders.koch@prostatypegenomics.com and at the Company's address Augustendalsvägen 20, 131 52 Nacka Strand. The Company's website is www.protstatypegenomics.com.
1.3	**Name and contact details for competent authority that approved the prospectus**	The prospectus has been approved by the Swedish Financial Supervisory Authority, which can be reached by telephone at +46 8 408 980 00, by e-mail at finansinspektionen@fi.se, by post at Box 7821, SE-103 97 Stockholm and via the website www.fi.se. Please note that the translated version has not been reviewed or approved by the Swedish Financial Supervisory Authority. In case of a discrepancy, the Swedish original version will prevail.
1.4	**Date of approval**	The prospectus has been approved on 16 May 2025. Please note that the translated version has not been reviewed or approved by the Swedish Financial Supervisory Authority. In case of a discrepancy, the Swedish original version will prevail.
1.5	**Varning**	This summary should be read as an introduction to the EU Growth Prospectus and any decision to invest in the securities should be based on a full reading of the prospectus. The investor may lose all or part of his invested capital. If a claim relating to information contained in an EU Growth prospectus is brought before a court, the investor who is the plaintiff under the national law of the Member States may have to pay the cost of translating the EU Growth prospectus before the legal proceedings are initiated. Civil liability extends only to the persons who have presented the summary, including translations thereof, but only if the summary is misleading, inaccurate or inconsistent with the other parts of the EU Growth prospectus or if, taken together with the other parts of the EU Growth prospectus, it does not provide the key information necessary for investors to decide whether to invest in the securities concerned.

SECTION 2 – KEY INFORMATION ABOUT THE ISSUER

2.1	**Information about the issuer**	Prostatype Genomics is a Swedish public limited liability company that was registered on 12 March 2007 and whose operations are conducted under Swedish law. The Board of Directors has its registered office in the municipality of Stockholm. Prostatype Genomics' operations are governed by the Swedish Companies Act (2005:551). The Company specialises in the development of medical genetic tests used for the identification, analysis and further follow-up of prostate cancer. The CEO of the Company is Fredrik Rickman. The name of the security is 'PROGEN'. The table below shows the Company's shareholders whose holdings corresponded to at least five percent of the shares and votes in Prostatype Genomics as of 31 March 2025, with known changes thereafter. As far as the Board of Directors is aware, the Company is not directly or indirectly controlled by any shareholder or group of shareholders.

Shareholder	**Votes and capital (%)**
Johan Waldhe[1]	10.55
Villa Drevan AB / Filip Norlin	10.24
JDS Invest AB / Håkan Englund[2]	9.54
Life Science Invest Fund 1 ApS / Dansktysk Ejendomsrådgivning Aps / Jan Poulsen	6.44
Bäverstenen AB / Hans Öhman	5.45
Others	*57.78*
Total	**100.00**

[1] Previous board member of the Company.
[2] Board member of the Company.

2.2	**Financial key infomation**	This section presents certain summarised financial information taken from Prostatype Genomics' audited annual reports for the financial years 2023 and 2024. The Company's accounts are prepared in accordance with K3.

Revenue and profitability, group

KSEK	**Jan-Dec 2024***	**Jan-Dec 2023***
Net turnover	199	1,356
Operating result	-40,853	-39,247
Result for the period	-41,051	-41,435

** audited*

Assets and capital structure, group

KSEK	**31 Dec 2024***	**31 Dec 2023***
Assets	41,970	49,222
Equity	33,469	24,674

** audited*

Cashflow, group

KSEK	Jan-Dec 2024*	Jan-Dec 2023*
Cash flow from operating activities	-44,709	-29,138
Cash flow from investing activities	-8,356	-8,566
Cash flow from financing activities	59,751	28,911
Cash flow for the period	6,686	-8,793

** ausited*

Key figures, group

KSEK	Jan-Dec 2024*	Jan-Dec 2023*
Net turnover	199	1,356
Balance sheet total	41,970	49,222
Result after financial items	-41,051	-41,435
Operating margin	Neg	Neg
Profit margin	Neg	Neg
Return on equity	Neg	Neg
Equity	33,469	24,674
Cashflow	6,686	-8,793
Result per share**	-6.12	-346.85
Solidity %	80	50

** audited*

*** comparative earnings per share figures for the comparative year have been restated to reflect the 1000:1 reverse split decided at the extraordinary general meeting on 22 October 2024*

Disclosure by the Company's auditor in the auditor's report in the annual report 2024

We draw the attention to the text in the Board of Directors' Report under the section Financing, liquidity and capital needs and disclosure note 2 under the heading Capital needs and going concern, which states that the Company does not have sufcient working capital to fnance operations in 2025, but that the Board of Directors is actively working to solve the capital requirements. If the outcome of this is not as expected,there is signifcant uncertainty about the Company's ability to continue operations. We would also like to draw attention to the text in the Directors' Report under the section Valuation of assets, where it is clear that there is a risk that if the Company's objectives are not achieved within the planned timeframe, it may lead to the intangible assets being amortised at a faster rate, or completely.

Remark from the Company's auditor in the auditor's report in the annual report 2024

On several occasions during the fnancial year, withheld tax, social security contributions and value added tax have not been paid on time. The Board of Directors has thus not fulfilled its obligations under the Companies Act, but the omissions have not caused any damage to the Company, apart from interest on late payments.

Disclosure by the Company's auditor in the auditor's report in the annual report 2023

We would like to draw attention to the text in the Administration Report under the section Capital requirement which states that the Company does not have sufficient working capital to finance its operations in 2024, and that the Board of Directors is actively working to solve the need of capital. If the outcome does not meet the Board of Directors' expectations, there is a material uncertainty of the Company's ability to continue its operations. We would also like to draw attention to the text in the section Valuation of assets, where it is stated that there is a risk that if the Company's budgets and forecasts are not achieved within the planned timeframe, it may lead to increased or complete write offs of the intangible assets.

2.3 Main risks that are specific for the Company

Market acceptance

At the date of this prospectus, sales of Prostatype® have been initiated in Sweden, Germany, Taiwan, Spain, Italy and Switzerland and in the future the Company aims to launch the product in the United States. However, there is a risk that sales will not fully fulfil the Company's objectives and that the product will not be commercially successful. If the Company and its product do not receive sufficient attention in the right channels, there is a risk of causing delays in the market acceptance of Prostatype® or that such acceptance will not materialise in whole or in part.

Overall, Prostatype Genomics assesses that the probability of the risk occurring is medium. The Company further assesses that the risk, if realised, would have a high impact on the Company.

Future financing need

The Company has been operating at a loss since its inception due to costs such as research and development and studies. Additional financing in the form of loans or other external financing may therefore be required to fund working capital needs. There is a risk that the Company will not be able to raise additional capital or that such financing cannot be obtained, which could slow down the commercialisation of Prostatype® and force the Company to operate at a slower pace than desired, which could lead to delayed or lost revenues from, among other places, the United States. This scenario could have a negative impact on the Company's operations, financial position and earnings.

Prostatype Genomics assesses the probability of the risk occurring as medium. The Company further assesses that the risk, if realised, would have a medium impact on the Company.

Dependence on key personnel

Prostatype Genomics is a small organisation that currently has six permanent employees. Due to the size of the organisation and each employee's experience in the field, each employee is considered to be a key person on whom the Company's operations are dependent in various respects. If most key employees were to leave within a short period of time, it would have a significant negative impact on the Company's ability to conduct its business and achieve the results it seeks. It could also delay the Company's operations and adversely affect its ability to achieve commercial goals.

Prostatype Genomics assesses the probability of the risk occurring as low. The Company further assesses that the risk, if realised, would have a high impact on the Company.

THIS IS A TRANSLATION OF THE ORIGINAL VERSION IN SWEDISH FOR INFORMATION PURPOSES ONLY.
IN CASE OF A DISCREPANCY, THE SWEDISH ORIGINAL WILL PREVAIL.

SECTION 3 – KEY INFORMATION ABOUT THE SECURITIES

3.1	**Information about the securities, rights connected to the securities and dividend policy**	The securities covered by the Offering are units consisting of shares with ISIN code SE0023261532 and warrants of series TO5 with ISIN code SE0024990063. The Company has only one class of shares and all outstanding shares are fully paid. The number of shares in Prostatype Genomics before the Offering amounts to 6,835,213, each with a quota value of SEK 0.10. Warrants of series TO5, which are issued free of charge in the Rights Issue, entitle the holder to subscribe for one (1) new share in Prostatype Genomics during the period 3-17 September 2025 for each (1) warrant at an exercise price corresponding to a 30 percent discount compared to the volume-weighted average share price during the twenty days prior to the exercise period, however, not less than SEK 0.10 (the share's quota value) and not more than SEK 1.50 per new share. The warrants are denominated in SEK, are not subject to any dividend or payment policy, do not entitle to dividends and do not entitle to attend or vote at general meetings of the Company. The shares in Prostatype Genomics have been issued in accordance with the Swedish Companies Act (2005:551) and the rights associated with the shares issued by the Company, including the rights arising from the Articles of Association, may only be amended in accordance with the procedures set out in this Act. Each share entitles the holder to one (1) vote at the General Meeting. Each shareholder entitled to vote may vote at the General Meeting for the full number of shares owned and represented by him. If the Company decides to issue new shares, warrants or convertibles by way of a cash or set-off issue, the shareholders shall, as a general rule, have preferential subscription rights in proportion to the number of shares they already own. All shares carry equal rights to a share in the Company's profits and to any surplus in the event of liquidation. Decisions on dividends are made by the General Meeting and are paid through Euroclear. The right to any dividends shall accrue to those who are registered as holders of shares in the share register maintained by Euroclear on the record date for dividends set by the general meeting. The Company has not adopted a dividend policy. Prostatype Genomics is a growth company where generated profits are planned to be allocated to the development of the business. Against this background, the Company does not expect to pay any dividends in the next few years, but in the future, when the Company's results and financial position so permit, dividends may be paid.
3.2	**Place of trading of the securities**	Prostatype Genomics is traded on Nasdaq First North Growth Market, which is an alternative marketplace, classified as a growth market for small and medium-sized companies, which is governed by a special regulatory framework and does not have the same legal status as a regulated market. The newly issued shares and warrants in the Offering will be admitted to trading on Nasdaq First North Growth Market in connection with the registration of the new share issue by the Swedish Companies Registration Office.
3.3	**Guarantees to which the securities are subject**	Not applicable. The securities are not covered by guarantees.
3.4	**Main risks that are specific for the securities**	**Dilution in future share issues** The Company may need additional capital to finance its operations, which may dilute the interests of existing shareholders in the Company and may also affect the price of the shares. There is also a risk that additional financing on acceptable terms will not be available to the Company when required, or will not be available at all. If these risks were to materialise, they could have a material adverse effect on shareholders' financial interests, investors' invested capital and/or the price of the shares. Prostatype Genomics considers that the probability of the risk occurring is medium and that the impact of the risk, if realised, would be medium. **Shareprice development** There is no guarantee that the share price of Prostatype Genomics will develop favourably and there is a risk that investors in the Company will not, in whole or in part, recover the capital invested. The Company's share price may develop negatively as a result of, for example, market expansion and sales growth taking longer than expected. There is a risk that the Company's share price may fluctuate sharply in the future, primarily as a result of major changes in buying and selling volumes, which are not necessarily related to Prostatype Genomics' underlying value. The Company's share price may be subject to extreme price and volume fluctuations that are not related or proportionate to the operational performance of Prostatype Genomics. Prostatype Genomics assesses that the probability of the risk occurring is low and that the effect of the risk, if realised, would be medium. **Shareholders with significant influence** Management and the Board of Directors own shares in Prostatype Genomics and, together with major shareholders, are able to exercise significant influence over matters submitted to the Company's shareholders for approval at a general meeting, including the election of directors, the issuance of additional shares or equity-related securities that may result in dilution for existing shareholders, decisions on any dividend and future acquisitions or sales of all or parts of the business. There is a risk that the above may be to the detriment of other shareholders who may have different interests from the main shareholders. Apart from applying the protective rules that follow from law, Prostatype Genomics has no possibility to take measures to guarantee that this influence is not abused. There is also a risk that the Company's share price could fall significantly if board members, senior executives or major shareholders sell shares in the Company, which could have a negative impact on the Company's share price. The Company considers that the potential likelihood of the risk occurring is low and that the impact of the risk, if realised, would be medium.

THIS IS A TRANSLATION OF THE ORIGINAL VERSION IN SWEDISH FOR INFORMATION PURPOSES ONLY.
IN CASE OF A DISCREPANCY, THE SWEDISH ORIGINAL WILL PREVAIL.

SECTION 4 – KEY INFORMATION ABOUT THE OFFERING OF SECURITIES TO THE GENERAL PUBLIC

4.1 Terms and timing of investing in the securities

The Offering

At the Annual General Meeting on 15 May 2025, the Meeting resolved to approve the Board's decision to increase the Company's share capital by an initial maximum of SEK 2,734,085.20 through a Rights Issue of units by a maximum of 6,835,213 units, corresponding to a maximum of 27,340,852 shares, each with a quota value of SEK 0.10 per share. Provided that the Rights Issue is fully subscribed, the share capital after the Rights Issue will amount to SEK 3,417,606.50 and the quota value to SEK 0.10 per share. The general public is also entitled to subscribe for units in the Rights Issue. The total initial issue amount for the Rights Issue amounts to a maximum of SEK 27,340,852.00.

Provided that the Rights Issue is oversubscribed, the Board of Directors of Prostatype Genomics may, with the support of authorisations from the Annual General Meeting, decide to issue additional units on the same terms as in the Rights Issue, up to approximately 15 percent of the total number of units offered through the Rights Issue. At the time of the issuance decision, the Board of Directors shall decide on allotment in accordance with the principles for allotment in the Rights Issue. The right to subscribe for units in the expanded offering shall accrue to those who subscribe for units in the Rights Issue without receiving full allotment.

Preferential subscription rights

Those who on the record date 19 May 2025 are registered as shareholders in the share register kept by Euroclear on behalf of the Company have preferential rights to subscribe for new units in proportion to the number of shares held on the record date. For each existing share held on the record date, one (1) unit right is received. The unit rights entitle the holder to subscribe for new units with preferential rights, whereby one (1) unit right entitles the holder to subscribe for one (1) new unit. One (1) unit consists of four (4) shares and three (3) warrants of series TO5.

Issue volume

The Offering comprises a maximum of 6,835,213 units (shares and attached free warrants of series TO5). The total initial issue amount amounts to a maximum of approximately SEK 27.3 million before issue costs.

Subscription price

The subscription price is SEK 4.00 per unit, which corresponds to SEK 1.00 per share. Warrants of series TO5 are issued free of charge. There is no brokerage fee.

Subscription period

Subscription of shares by virtue of unit rights shall take place during the period from 21 May 2025 up to and including 4 June 2025. The Board of Directors of the Company reserves the right to extend the subscription period. Any extension will be announced by the Company through a press release no later than 4 June 2025.

Trading in unit rights

Trading in unit rights will take place on Nasdaq First North Growth Market during the period 21 May 2025 to 30 May 2025. Shareholders should contact their bank or other nominee with the necessary authorisations directly to purchase and sell unit rights. Unit rights acquired during the above-mentioned trading period give, during the subscription period, the same right to subscribe for shares as the unit rights shareholders receive based on their holdings in the Company on the record date.

Trading in BTU

Trading in BTUs will take place on Nasdaq First North Growth Market from 21 May 2025 until the Rights Issue has been registered with the Swedish Companies Registration Office. Subscribed shares are booked as BTUs on the subscriber's securities account or custody account until the Rights Issue has been registered with the Swedish Companies Registration Office, which is expected to take place in mid-June 2025.

Unit rights

For each existing share held on the record date, one (1) unit right is received. Unit rights entitle the holder to subscribe for new units with preferential rights, whereby one (1) unit right entitles the holder to subscribe for one (1) unit. One (1) unit consists of four (4) shares and three (3) warrants of series TO5.

Subscription without preferential right

Subscription of units without preferential rights shall take place during the same period as subscription of units with preferential rights, i.e. from 21 May 2025. The Board of Directors of the Company reserves the right to extend the subscription period and the time for payment in all circumstances. Such an extension shall be announced no later than the last day of the subscription period and published by the Company. Application to subscribe for units without preferential rights shall be made on Nordic Issuing's platform https://minasidor.nordic-issuing.se/. For nominee registered shareholders, application for subscription of units without preferential rights shall be made to the respective nominee and in accordance with instructions from the nominee, or if the holding is registered with several nominees, from each of them. In order to be able to invoke subsidiary preferential rights, it is required that the subscription is carried out via the nominee as there is otherwise no possibility to identify a specific subscriber who has subscribed for units both with and without the support of unit rights. Incomplete or incorrectly completed subscriptions may be disregarded. It is only permitted to apply for a 'Subscription without unit rights'. The subscription must be made no later than 4 June 2025. The application is binding.

Allotment in the event of subscription without preferential rights

In the event that not all units are subscribed for with the support of unit rights, the board of directors shall, within the scope of the maximum amount of the issue, decide on the allocation of units that have not been subscribed for with preferential rights. Such allocation shall primarily be made to subscribers who have subscribed for units with the support of unit rights, regardless of whether the subscriber was a shareholder on the record date for the issue or not, and, in the event of oversubscription, pro rata in relation to the number of units subscribed for with the support of unit rights. Secondly, allocation shall be made to those who have subscribed for units without the support of unit rights and, in the event of oversubscription, pro rata in relation to the number of units subscribed for in the application, and, to the extent that allocation cannot be made pro rata, by drawing lots. Thirdly, allocation shall be made to guarantors in accordance with the terms of the issued guarantee commitments

Dilution

Through the Rights Issue, the Company's share capital may initially increase by a maximum of SEK 2,734,085.20 through the issuance of up to 27,340,852 shares, corresponding to approximately 80 percent of the votes and capital in the Company. The dilution is based on the number of

shares issued after full subscription of the Rights Issue. In the event of full exercise of the warrants of series TO5 within the framework of the Rights Issue, the share capital may increase by an additional maximum of SEK 2,050,563.90, corresponding to an additional approximately 38 percent of the votes and capital in the Company. If the Extended Offer is activated, the Company's share capital may be increased by an additional maximum of SEK 410,112.80 through the issuance of up to 4,101,128 shares, corresponding to approximately 10.7 percent of the votes and capital in the Company, and by a further maximum of SEK 307,584.60 through the issuance of up to 3,075,846 shares, corresponding to approximately 5.3 percent of the votes and capital in the Company, through the exercise of attached warrants of series TO5 in the Extended Offer. Should the guarantors entitled to compensation choose such compensation in the form of units, the Company's share capital may increase by an additional maximum of SEK 282,420.00 through a directed issue of up to 2,824,200 shares, corresponding to approximately 7.6 percent of the votes and capital in the Company, and by a further maximum of SEK 211,815.00 through the issuance of up to 2,118,150 shares, corresponding to approximately 3.7 percent of the votes and capital in the Company, through the exercise of attached warrants of series TO5.

Publication of the Outcome of the Rights Issue

The outcome of the Rights Issue will be announced through a press release planned for around 5 June 2025, or as soon as possible after the subscription period has ended. The Company will publish the outcome of the Rights Issue via a press release.

Costs of the Rights Issue

The issuance costs for the initial part of the Rights Issue are expected to amount to a maximum of approximately SEK 4.9 million, including compensation to the bottom guarantors of approximately SEK 1.9 million (assuming they choose cash compensation). The total issuance costs (including compensation to guarantors) correspond to approximately 17.9 percent of the total initial proceeds from the Rights Issue. The terms of the TO5 series warrants include a strike price equal to 70 percent of the volume-weighted average share price over twenty trading days preceding the exercise period, with a minimum price corresponding to the quota value of the share (SEK 0.10 per share) and a maximum price of SEK 1.50 per share. To the best of the Company's knowledge, transaction costs in connection with the exercise of TO5 series warrants are estimated to amount to approximately 9.3 percent of the proceeds from the warrants.

4.2 Reasons for the Offering and use of proceeds

Reasons for the Offering

In order to more effectively commercialize and market Prostatype Genomics' genetic test, Prostatype®, in the United States, the Company is awaiting Medicare approval. The Company submitted its application in September 2024 and has since provided responses to supplementary questions. The timing of the approval is difficult for the Company to estimate, as it depends on processes within U.S. regulatory authorities. The Company is working with both Swedish and U.S. legal counsel in this matter and assesses that approval can reasonably be expected to be obtained during 2025. With Medicare approval in place, the Board of Directors believes that Prostatype Genomics will be well positioned to commercialize its kit in the U.S. market.

According to the Board of Directors' assessment, the existing working capital is not sufficient to meet the Company's needs for the coming 12 months from the date of this prospectus. In order to finance the repayment of outstanding bridge loans and related interest, as well as to support the aforementioned corporate development, Prostatype Genomics is conducting the Rights Issue, which has a maximum issue volume of approximately SEK 27.3 million (before transaction costs of approximately SEK 4.9 million, which include cash compensation to bottom guarantee underwriters).

With the maximum net proceeds of approximately SEK 22.4 million from the Rights Issue (after transaction costs), the Company intends to finance the following activities, listed in order of priority:

- Repayment of bridge loans from Exelity AB, Buntel AB, and Oliver Molse – approximately 22.3 percent of the proceeds
- Payment of interest costs and setup fees related to the above bridge loans – approximately 2.1 percent of the proceeds
- Completion of U.S. validation study and Medicare approval process – approximately 5.6 percent of the proceeds
- Ongoing commercialization activities in the U.S. and Europe, as well as strengthening working capital and ongoing operational activities – approximately 70.0 percent of the proceeds

With the net proceeds from the exercise of TO5 series warrants (after transaction costs), totaling approximately SEK 27.9 million, the Company intends to finance the following activity, listed in order of priority:

- Scale-up of commercialization and organizational operations in the U.S., as well as ongoing operational expenses – 100 percent of the proceeds

To accommodate any potential oversubscription in the Rights Issue, the Company's Board of Directors may resolve to extend the offering by issuing up to an additional 1,025,282 units, corresponding to 4,101,128 shares and 3,075,846 warrants of series TO5 (the "**Extended Offering**"). This represents an issue volume of approximately SEK 4.1 million before transaction costs and accounts for approximately 15 percent of the total number of units that may be issued through the Rights Issue. The associated costs for the Extended Offering are estimated at approximately SEK 0.7 million. The net proceeds from the Extended Offering, amounting to a maximum of approximately SEK 3.4 million, are intended to be used for commercialization efforts in the U.S. Through the warrants of series TO5 that may be issued under the Extended Offering, the Company may receive up to an additional SEK 4.6 million before transaction costs. The transaction costs related to the exercise of these warrants are estimated at approximately SEK 0.4 million, resulting in net proceeds of approximately SEK 4.2 million, which are also intended to be used for commercialization efforts in the U.S.

In the event that the Rights Issue is not fully subscribed, Prostatype Genomics will – after repayment of previously mentioned loan and setup fee as well as interest relating to the loan – prioritize activities focused on the U.S. market. The Board of Directors believes that the net proceeds from a fully subscribed initial Rights Issue will be sufficient to finance the Company's ongoing operations and strategic plans through Q4 2025. If the warrants of series TO5 are exercised, the Company would be financed for a longer period, depending on the degree of exercise and the applicable strike price. If the initial Rights Issue and the associated warrants of series TO5 are not subscribed for and exercised to the extent required to secure the Company's working capital needs for the coming 12-month period, despite the guarantee commitments, the Board of Directors intends to explore alternative financing options. These may include additional capital raising, debt financing, or operating the business at a slower pace than currently planned until further capital can be secured. In such a scenario, the Company will focus on activities deemed most critical to its development.

Subscription Commitments and Guarantee Undertakings

Approximately SEK 22.1 million of the Rights Issue is covered by subscription commitments and guarantee undertakings, corresponding to approximately 81 percent of the total maximum initial issue volume. Of this amount, approximately SEK 3.4 million, corresponding to around 12.6 percent, refers to subscription commitments. Approximately SEK 11.7 million, or about 42.9 percent, relates to bottom guarantee undertakings

(up to approximately 55.5 percent). Approximately SEK 4 million, corresponding to about 14.5 percent, pertains to top guarantee undertakings (top-down, from 100 percent downward), and SEK 3 million, corresponding to approximately 11 percent, relates to a second tranche of top guarantee undertakings (top-down, from 85.15 percent downward).

For the bottom guarantee undertakings, a guarantee fee of 16 percent in cash or 20 percent in the form of newly issued units (issued on the same terms as the Rights Issue) is payable. For the second tranche top guarantee undertaking (top-down from 85.15 percent), the fee is 16 percent in the form of newly issued units, also issued on the same terms as the Rights Issue. No guarantee fee is paid for the top guarantee undertaking (top-down from 100 percent).

Interests and Conflicts of Interest

Gemstone and Navia, the financial advisors to the Company in the Rights Issue, may in the future provide various financial, investment, commercial, and other services to Prostatype Genomics. Gemstone and Navia receive a pre-agreed fee for services rendered in connection with the Offering. In addition, Gemstone and Navia receive compensation based on the outcome of the Offering, thus creating an interest in the Offering itself. Lindahl receives compensation for services rendered on an hourly basis. Board member Mattias Prage is also a shareholder and attorney at Lindahl.

Apart from the interests of Gemstone, Navia, or Lindahl in ensuring the successful execution of the Rights Issue and the payment of agreed compensation concerning guarantee undertakings, there are no economic or other interests, nor any conflicts of interest, between the parties involved in the Rights Issue as described above.

THIS IS A TRANSLATION OF THE ORIGINAL VERSION IN SWEDISH FOR INFORMATION PURPOSES ONLY.
IN CASE OF A DISCREPANCY, THE SWEDISH ORIGINAL WILL PREVAIL.

RESPONSIBLE PERSONS, INFORMATION FROM THIRD PARTIES, AND APPROVAL BY COMPETENT AUTHORITIES

RESPONSIBLE PERSONS

The Board of Directors of Prostatype Genomics AB is responsible for the content of this prospectus. To the best of the Board's knowledge, the information provided in the prospectus is accurate and complete, and no information that could reasonably be expected to affect the contents has been omitted. Below is the presentation of the Board of Directors of Prostatype Genomics. For full details about the Board, please refer to the section 'Board of Directors and Executive Management' in this prospectus.

Position	Name
Chairman of the Board	Anders Lundberg
Board member	Jörgen Dahlström
Board member	Håkan Englund
Board member	Michael Häggman
Board member	Mattias Prage

PREPARATION AND REGISTRATION OF THE PROSPECTUS

The prospectus has been approved by the Swedish Financial Supervisory Authority (Finansinspektionen) as the competent authority in accordance with Regulation (EU) 2017/1129. The Financial Supervisory Authority approves this prospectus solely in so far as it meets the requirements of completeness, clarity, and consistency set out in Regulation (EU) 2017/1129. This approval should not be construed as an endorsement of the issuer or of the quality of the securities referred to in this prospectus. Investors should make their own assessment of whether it is appropriate to invest in these securities. The prospectus has been prepared as an EU Growth Prospectus in accordance with Article 15 of Regulation (EU) 2017/1129.

INFORMATION FROM THIRD PARTIES

The prospectus contains information from third parties. The Board of Directors confirms that information from third parties has been reproduced accurately, and to the best of the Board's knowledge and based on publicly available information from third parties, no material facts have been omitted that would make the information provided inaccurate or misleading. The third-party sources used by Prostatype Genomics in the preparation of this prospectus are listed in the source reference below.

SOURCE REFERENCES

- Bill-Axelson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, Häggman M, Andersson SO, Andrén O, Steineck G, Adami HO, Johansson JE. Radical Prostatectomy or Watchful Waiting in Prostate Cancer – 29-Year Follow-up. N Engl J Med. 2018 December 13;379(24):2319-2329. Doi: 10.1056/NEJMoa1807801. PMID: 30575473.
- Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003 Juni 18;95(12):868-78. Doi: 10.1093/jnci/95.12.868.
- Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014 Jun;65(6):1046-55. Doi: 10.1016/j.eururo.2013.12.062. Epub 2014 Januari 9. PMID: 24439788; PMCID: PMC4113338.
- Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 April;10(2):63-89. Doi: 10.14740/wjon1191. Epub 2019 April 20. PMID: 31068988; PMCID: PMC6497009.
- Sandström J, Wikström P, Tysell E, Bergh A. Phenotype Diagnostics – Novel method for risk assessment and treatment stratification in men with prostate cancer. Umeå Biotech Incubator. https://www.ubi.se/case/novel-method-for-risk- assessment-and-treatment-stratification-in-men-with-prostate-cancer/, hämtad 2023.
- Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009 Mars 26;360(13):1320-8. Doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18. PMID: 19297566.
- Taitt HE. Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. Am J Mens Health. 2018 Nov;12(6):1807-1823. Doi: 10.1177/1557988318798279. Epub 2018 September 11. PMID: 30203706; PMCID: PMC6199451.
- van den Bergh RC, Korfage IJ, Roobol MJ, Bangma CH, de Koning HJ, Steyerberg EW, Essink-Bot ML. Sexual function with localized prostate cancer: active surveillance vs radical therapy. BJU Int. 2012 Oct;110(7):1032-9. Doi: 10.1111/j.1464- 410X.2011.10846.x. Epub 2012 Jan 19. PMID: 22260273.
- Vården.se (2022). Prostatacancer – Sveriges vanligaste cancerform. https://www.varden.se/blogg/2304-prostatacancer- sveriges-vanligaste-cancerform, hämtad 2023.

BACKGROUND AND MOTIVE

MOTIVE FOR THE RIGHTS ISSUE

To more effectively commercialize and market Prostatype Genomics' genetic test Prostatype® in the USA, the Company is awaiting Medicare approval for reimbursement. The Company's application was submitted in September 2024, and since then, responses to additional questions have been submitted. The timing for approval is difficult for the Company to estimate, as it depends on processes with regulatory authorities in the USA. The Company is working with both Swedish and American lawyers on the matter, and it is anticipated that approval is reasonably likely to be obtained during 2025. Once Medicare approval is secured, the Board's assessment is that Prostatype Genomics will be well-positioned to commercialize Prostatype® in the USA.

The existing working capital is, according to the Board, not sufficient for the Company's needs for the 12-month period following the date of this prospectus. To finance the repayment of outstanding bridge loans and their interest, as well as the aforementioned corporate development, Prostatype Genomics is conducting a Rights Issue with a maximum issue volume of approximately SEK 27.3 million (before issuance costs of approximately SEK 4.9 million, including cash compensation to bottom guarantee providers). With the funds the Company expects to raise through the Rights Issue (after costs), approximately SEK 22.4 million, the Company's intention is to finance the following listed activities (in order of priority):

- Repayment of bridge loans from Exelity AB, Buntel AB, and Oliver Molse – approximately 22.3% of the issue proceeds
- Payment of interest costs and setup fees related to the aforementioned bridge loans – approximately 2.1% of the issue proceeds
- Completion of the validation study in the USA and Medicare approval process – approximately 5.6% of the issue proceeds
- Ongoing commercialization activities in the USA and Europe, as well as strengthening working capital and ongoing operational activities – approximately 70.0% of the issue proceeds

Through the funds the Company will raise through the TO5 series warrants (after issuance costs), totaling approximately SEK 27.9 million, the Company's intention is to finance the following activity:

- Ramp-up of commercialization and organization in the USA as well as ongoing operational costs – 100% of the issue proceeds

To accommodate any oversubscription of the Rights Issue, the Board of Directors may decide to implement the Expanded Offer to issue an additional maximum of 1,025,282 units, corresponding to 4,101,128 shares and 3,075,846 warrants of series TO5, which initially corresponds to an issue volume of approximately SEK 4.1 million before issuance costs and corresponds to about 15% of the total number of units that can be issued through the Rights Issue. Costs related to the Expanded Offer amount to approximately SEK 0.7 million. The net proceeds from the Expanded Offer, which amount to a maximum of approximately SEK 3.4 million, are intended to be used for commercialization efforts in the USA. Through the TO5 series warrants that can be issued through the Expanded Offer, the Company can raise an additional maximum of SEK 4.6 million before issuance costs. The costs for exercising the TO5 series warrants issued through the Expanded Offer are expected to amount to approximately SEK 0.4 million, resulting in net proceeds of approximately SEK 4.2 million, which are intended to be used for commercialization efforts in the USA.

In the event of an undersubscribed Rights Issue, Prostatype Genomics will – after repayment of previously mentioned loan and setup fee as well as interest relating to the loan – prioritize activities aimed at the USA. The Board's assessment is that the net proceeds from a fully subscribed initial Rights Issue are sufficient to finance the Company's ongoing operations and plans through Q4 2025. If the TO5 warrants are exercised, the Company will be financed for a longer period, depending on the extent to which these are exercised and at what exercise price. If the initial Rights Issue and the attached TO5 warrants are not subscribed or exercised to the extent that the Company's working capital is secured for the coming twelve-month period, despite guarantee commitments, the Board intends to explore alternative financing options, such as further capital raising, loan financing, or conducting the operations at a slower pace than planned until additional capital can be raised. The Company will then focus on the activities deemed most necessary for its development.

SUBSCRIPTION COMMITMENTS AND GUARANTEE UNDERTAKINGS

Approximately SEK 22.1 million of the Rights Issue is covered by subscription commitments and guarantee undertakings, which corresponds to 81% of the total maximum initial issue volume. Of this, approximately SEK 3.4 million, corresponding to approximately 12.6%, relates to subscription commitments. Approximately SEK 11.7 million, corresponding to approximately 42.9%, refers to bottom guarantees (from the subscription commitments up to approximately 55.5% of the issue volume), approximately SEK 4 million, corresponding to approximately 14.5%, refers to top guarantees (top-down, from 100% down), and SEK 3 million, corresponding to

approximately 11%, refers to top guarantees in a second tranche (top-down, from 85.15% down). For the bottom guarantee commitment, a guarantee compensation of 16% in cash or alternatively 20% in the form of newly issued units, which will be issued on the same terms as the Rights Issue, will be provided. For the top guarantee commitment in the second tranche (top-down, from 85.5% down), compensation of 16% in the form of newly issued units, which will be issued on the same terms as the Rights Issue, will be provided. No guarantee compensation will be provided for the top guarantee commitment (top-down, from 100% down). No compensation is provided for the subscription commitments that have been made. Subscription commitments and guarantee undertakings are not secured through pre-agreements, bank guarantees, or similar. More information about subscription commitments and guarantee undertakings can be found in the section 'Terms and Instructions' of this prospectus.




Illustration of subscription commitment and guarantee commitment arrangements in the Rights Issue

Example

In the event that the Rights Issue is fully subscribed, neither the bottom guarantee commitment nor any of the top guarantee tranches will be activated. If, on the other hand, the Rights Issue is subscribed to approximately 80 percent by subscribers and other existing shareholders and/or the general public, the top guarantee at the level of 100-85.5 percent will be fully activated and the top guarantee at the level of 85.5-74.5 percent will be partially activated (5.5 percent). The bottom guarantee is not activated in such an example, as it 'only' extends up to around 55.5 percent. The outcome in such an example is that the subscription ratio, including the subscription commitment and guarantee, will be 100 percent in total.

In the event that the Rights Issue is subscribed to approximately 60 percent by subscribers and other existing shareholders and/or the general public, the top guarantee at the level of 100-85.5 percent and the top guarantee at the level of 85.5-74.5 percent will be fully activated. The bottom guarantee is not activated in such an example, as it 'only' extends up to around 55.5 percent. The outcome in such an example is that the subscription ratio, including subscription commitment and guarantee, will be a total of 85.5 percent (subscription commitment and existing owners/general public totalling 60 percent and activated top guarantee tranches totalling 25.5 percent).

In the event that the Rights Issue is subscribed to approximately 40 percent by subscribers and other existing shareholders and/or the general public, the top guarantee at the level of 100-85.5 percent and the top guarantee at the level of 85.5-74.5 percent will be fully activated. The bottom guarantee is activated in such an example with 15.5 percent of the issue volume, to cover up to the level to which it extends (approximately 55.5 percent). The outcome in such an example is that the subscription rate, including subscription commitment and guarantee, will be a total of 81 percent (subscription commitment and existing owners/the general public totalling 40 percent, activated bottom guarantee of 15.5 percent and activated top guarantee tranches totalling 25.5 percent)

ADVISORS

Financial Advisors to the Company are Gemstone and Navia, and Legal Advisor is Lindahl. Since all information in the prospectus originates from the Company, Gemstone, Navia, and Lindahl disclaim any responsibility towards existing or future shareholders of the Company and regarding other direct or indirect economic consequences resulting from investment or other decisions that are wholly or partly based on information in the prospectus. Nordic Issuing is the issuing agent in connection with the Rights Issue.

INTERESTS AND CONFLICTS OF INTEREST

Gemstone and Navia are financial advisors, and Lindahl is the legal advisor to the Company in connection with the Offer. Gemstone and Navia provide, and may in the future provide, various financial, investment, commercial, and other services to Prostatype Genomics. Gemstone and Navia receive a pre-agreed fee for services rendered in connection with the Offer. Additionally, Gemstone and Navia receive compensation based on the outcome of the Offer, meaning they have an interest in the Offer itself. Lindahl is compensated for services rendered based on ongoing fees. Board member Mattias Prage is also a co-owner and lawyer at Lindahl. Beyond this, neither Gemstone, Navia, nor Lindahl have any economic or other interests in the Rights Issue.

Aside from the above-mentioned parties' interest in the successful completion of the Rights Issue, and regarding guarantee commitments to ensure the agreed compensation is paid, it is assessed that no economic or other interests, nor conflicts of interest, exist between the parties with economic or other interests in the Rights Issue, as stated above.

THIS IS A TRANSLATION OF THE ORIGINAL VERSION IN SWEDISH FOR INFORMATION PURPOSES ONLY.
IN CASE OF A DISCREPANCY, THE SWEDISH ORIGINAL WILL PREVAIL.

BUSINESS- AND MARKET OVERVIEW

ABOUT PROSTATE CANCER

Prostate cancer accounts for one-third of all cancer cases in men, making it the most common cancer type among men in Sweden, as well as in other Western European countries and the USA. In Sweden, approximately 10,000 men are diagnosed with the disease each year, making it the most common form of cancer in the country. The risk of developing prostate cancer increases with age, and half of those diagnosed are over 70 years old when the diagnosis is made. It may take a long time before the cancerous tumor presses enough on the urethra to cause urinary problems. Early-stage prostate cancer usually does not show any symptoms. In prostate cancer, a malignant tumor forms in the prostate, typically in the outer part of the gland.[1]

For some men, prostate cancer grows and spreads rapidly, making it a serious condition that requires aggressive and radical treatment. However, in approximately 80% of cases, the cancer grows slowly and typically only requires active monitoring rather than radical treatment. In fact, for most men diagnosed with prostate cancer, the tumor does not pose a threat to the patient's life and does not present specific symptoms in the early stages. However, in later stages, prostate cancer can cause pain, difficulty urinating, and problems with sexual activity.[2]

Due to the difficulty in determining the status of the cancer and how it will develop in the future, it is estimated that between 50% and 90% of patients (depending on geography) receive radical treatment for their prostate cancer, according to the Company's assessment based on official sources and presented scientific articles from various countries. Radical treatments include prostatectomy (where the prostate is surgically removed either partially or completely) and radiation. For most men diagnosed with prostate cancer, these treatments are chosen even though conservative strategies such as active monitoring of the cancer would be sufficient, as the mortality rate for prostate cancer is low.[3]

THE MARKET FOR PROSTATE CANCER

There is a global need for better prognostic tools. According to the Company's assessment, the annual global market potential for prostate cancer prognosis is approximately SEK 9.5 billion. The Company estimates that the annual addressable market for Prostatype Genomics amounts to a total of approximately SEK 6.5 billion, which corresponds to about 65% of the total market. Around 1.5 million men worldwide are diagnosed with prostate cancer annually[4], so the board estimates that about 900,000 patients can be added to the Company's addressable market each year. The number of newly diagnosed patients globally is expected to double by 2040. Additionally, there are men who are already diagnosed with prostate cancer but have not undergone radical treatment, where supplementary information is desirable. This patient group is also a target for Prostatype, and the Company estimates that around 5 million men globally are included in the target group.

The majority of patients are diagnosed in Western Europe and the USA. The Company's updated estimate of the US market for Prostatype, which is partly based on full-year figures for 2024 from the American competitor Veracyte[5], is that the existing annual US market amounts to at least SEK 4 billion (USD 375 million). In Asia, the growth of prostate cancer is increasing as PSA testing is introduced in various countries. [6] The global market's annual growth rate is estimated to be between 4-6% in the future.[7]

The average health economic value of Prostatype® is estimated to be between SEK 92,000 and SEK 158,000 per patient[8], which, just in Sweden, would correspond to reduced healthcare costs of approximately SEK 800 million annually. As a result, the Company expects that authorities will eventually include Prostatype® in the reimbursement system for men with predicted prostate cancer.

---

[1] *Vården.se (2022). Prostatacancer – Sveriges vanligaste cancerform. https://www.var- den.se/blogg/2304-prostatacancer-sveriges-vanligaste-cancerform, hämtad 2023.*

[2] *Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 April;10(2):63-89. doi: 10.14740/wjon1191. Epub 2019 April 20. PMID: 31068988; PMCID: PMC6497009.*

[3] *Bill-Axelson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, Häggman M, An- dersson SO, Andrén O, Steineck G, Adami HO, Johansson JE. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med. 2018 December 13;379(24):2319-2329. doi: 10.1056/NEJMoa1807801. PMID: 30575473*

[4] *Sandström J, Wikström P, Tysell E, Bergh A. Phenotype Diagnostics – Novel method for risk assessment and treatment stratification in men with prostate cancer. Umeå Biotech Incubator.https://www.ubi.se/case/novel-method-for-risk-assessment-and-treat- ment-stratification-in-men-with-prostate-cancer/, hämtad 2023.*

[5] *https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-fourth-quarter-and-full-year-2024-financial, hämtad 2025.*

[6] *Taitt HE. Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. Am J Mens Health. 2018 Nov;12(6):1807-1823. doi: 10.1177/1557988318798279. Epub 2018 September 11. PMID: 30203706; PMCID: PMC6199451.*

[7] *Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 April;10(2):63-89. doi: 10.14740/wjon1191. Epub 2019 April 20. PMID: 31068988; PMCID: PMC6497009.*

[8] *Baserat på extern beräkning av IHE – Institutet för Hälso- och Sjukvårdsekonomi, Lund, Sverige.*

Prostatype® is intended to be used as a complement to the current diagnostic tools and does not replace any existing procedures. No additional examination of the patient is required to perform the test. According to the Company's assessment, this results in low entry barriers in its target markets. Generally, the Company anticipates conducting limited validation and market studies before launching in certain markets. However, this is not a formal requirement, although it is common practice to conduct such studies.

CURRENT DIAGNOSTIC METHODS

The most common medical methods for diagnosing prostate cancer are:

- **PSA (Prostate-Specific Antigen)**
  A blood test that measures prostate-specific antigen (PSA) levels in the blood. Elevated PSA levels can indicate cancer but can also result from other conditions. Patients with elevated levels are referred to a urologist for further evaluation, including biopsy and, in some cases, MRI.

  Challenge: PSA levels are relatively non-specific and provide uncertain results. The test is not cancer-specific and cannot reliably distinguish between aggressive tumors and those that are indolent (slow-growing). Several studies show clear evidence that overdiagnosis and, consequently, overtreatment are significant negative consequences of PSA screening.

- **Biopsy and Gleason Score**
  If prostate cancer is suspected, the patient's urologist will collect several samples of prostate tissue (biopsy) to determine if cancer is present. A pathologist then examines the collected tissue samples under a microscope and grades them according to the Gleason scale. The score is determined on a scale from 2 (nearly normal) to 10 (very malignant). Urologists consider a Gleason score of 6 to be low risk, a score of 7 to be intermediate risk, and a score of 8 or higher as potentially aggressive. Based on multiple official sources and scientific articles from various countries, the Company estimates that about 65% of the total patient population has a score of 6 or 7, with the majority in the intermediate group in Western Europe and the USA.

  Challenge: Grading depends on the doctor's subjective assessment of prostate tissue samples. Two doctors may assess the same tissue sample differently. This can lead to different treatment strategies and result in the patient being over- or under-treated.

- **Digital Rectal Exam (DRE)**
  In this method, the doctor feels the prostate with a gloved finger through the rectum and can then determine if there are changes in the prostate.

  Challenge: This method is also dependent on the doctor's subjective assessment. There can be various reasons and underlying conditions that cause an enlarged or hard prostate during the examination. It should also be emphasized that this examination is entirely subjective, meaning that different doctors can make very different assessments of the prostate.

Current methods for diagnosing prostate cancer are thus reliant on visual assessment and human interpretation. Decisions regarding treatment strategies are therefore made based on subjective and qualitative information, which does not necessarily reflect the pathology of the individual patient's prostate cancer. As a result, a significant number of patients are misclassified, leading to overtreatment for some and undertreatment for others. Studies show that seven out of ten patients with prostate cancer are misdiagnosed and receive incorrect treatment for their cancer. This often results in significantly reduced quality of life for the patient due to lifelong side effects, which could have been avoided through optimal treatment. In many cases, optimal treatment means the patient is not actively treated but placed under active surveillance in the healthcare system.

COMPETITORS

Prostatype® does not replace the existing procedure, as the product provides complementary information regarding the prognosis of prostate cancer, which aids in selecting the optimal treatment strategy. At the time of the prospectus' publication, the Board, based on the Company's market activities in Europe, estimates that companies in Europe offering a genetic test similar to Prostatype® do so to a very limited extent, as there are currently no reimbursement models or procedures in place in Europe. Prognostic biomarkers are also not included in national guidelines in any European country, nor is there a recommendation from the European Association of Urology (EAU) as of the date of the prospectus. This means that companies with prognostic tests are currently primarily focusing on the U.S. market, which is described below.

In the U.S., there are three competitors, Exact Sciences, Veracyte, and Myriad Genetics, that offer tests focusing on conventional proliferation genes, as opposed to Prostatype's target genes, which are embryonic cancer stem cells. The price for end-users in the U.S. is higher than the estimated price for Prostatype® on the European market. Prostatype Genomics intends to apply for the same reimbursement (3,873 USD/test) that has already been established by the aforementioned competitors.

PROSTATYPE GENOMICS IN SHORT

The Company is the result of over fifteen years of research in the genomics of prostate cancer. It was founded in 2007 as a spin-off from the Cancer Center Karolinska (Karolinska Institute, Stockholm). The outcome was the development of the currently IVDR-approved and market-ready product, the Prostatype® Test System.

Prostatype® Test System

Prostatype® is a patented genetic test for prognosticating prostate cancer, developed to provide the complementary information often required to choose the optimal treatment strategy for each unique patient. The system in Prostatype® identifies the genetic fingerprint of prostate cancer by measuring gene expression in the genes of embryonic cancer stem cells in the tissue sample (biopsy) already obtained when the patient is diagnosed. In other words, Prostatype Genomics uses the patient's original biopsy, meaning that the patient does not need to undergo additional tests to diagnose prostate cancer while simultaneously increasing the precision of the treatment decision.

Prostatype® is intended to be used as a complement to the current clinical diagnostic and prognostic methods routinely used in healthcare. Prostatype® is patented and, in the opinion of the board, is the only genetic test for prostate cancer that focuses on measuring gene expression in embryonic cancer stem cells in prostate cancer in a format that allows independent laboratories to perform tests. Prostatype® includes four reagents sufficient to perform expression analysis of up to 16 patient samples.

The test analyzes gene expression in cancer cells from prostate tissue, and, combined with advanced algorithms and data analysis, provides decision support for the optimal treatment of individual patients once prostate cancer has been confirmed. Using AI technology (artificial intelligence), Prostatype Genomics' genetic test enables better prognostication of prostate cancer and categorization of the patient's condition into different risk types. In this way, the test can reduce the risk of overtreatment or undertreatment, which in many cases leads to significant patient suffering in the form of lifelong side effects such as impotence and incontinence.

The Prostatype Genomics Test System is a package consisting of the Prostatype® RTqPCR kit, patient databases and algorithms, PWS (Prostatype Web System), and the associated P-score.

Identification of three stem cell genes for cancer

Prostatype Genomics has identified three target genes, IGFBP3, F3, and VGLL3, which are correlated with both overall and prostate cancer-specific survival. Cancer stem cells define how aggressive and rapidly growing a tumor is, and therefore form the basis of the cancer, making them highly relevant for estimating the tumor's status and providing a very reliable prognosis. Gene expression is independent of specific tumor cells, meaning that potentially fewer biopsies are needed when using Prostatype®. The system in Prostatype® identifies the genetic fingerprint of the cancer by analyzing information from these cancer stem cell genes in the tissue sample (biopsy) that has already been obtained at the time of the patient's diagnosis. More specifically, Prostatype® quantifies RNA expression levels in these three embryonal stem cell genes in the individual patient's tumor, thereby providing valuable tumor biology that existing clinical pathological factors cannot currently offer.

Prostatype Web Services and P-score

The expression levels of the three stem cell genes, along with three other clinical parameters (Gleason score, PSA value, and tumor stage), are recorded in the Prostatype Web Services ('PWS') software, which is linked to several patent databases. These databases contain authentic historical information about patients, including various clinical parameters, treatments, and outcomes. The data comes from a patient base of approximately 4,000 patients, with around 600 patients added to the databases, providing between eight and twelve years of clinical follow-up, including survival time, cause of death, and treatment methods used. The databases have been made possible thanks to Sweden's personal identification number register and the national healthcare registration system, but also include data from other countries and populations.

By utilizing AI technology and machine learning, the Company has created several algorithms to calculate a P-score, a report that indicates how aggressive (or non-aggressive) the cancer is, which helps guide the selection of the optimal treatment strategy for the patient.

Business idea

Prostatype Genomics' business idea is to develop prognostic methods for prostate cancer that provide better decision-making support for patients and doctors regarding optimal treatment, as well as health-economic benefits to healthcare systems and society at large.

Mission

Prostatype Genomics' mission is to make a difference in the lives of patients diagnosed with prostate cancer by enhancing their quality of life and peace of mind, while also contributing health-economic benefits to society. The Company achieves this by discovering and commercializing transformative tests that provide guiding information for treatment decisions.

Vision

Prostatype Genomics' vision is that Prostatype® for newly diagnosed patients, or for patients under active monitoring, will be the test system recommended as the first choice for more precise treatment decisions in the case of diagnosed prostate cancer, from a global perspective.

Strategy

Prostatype Genomics has started the commercialization of Prostatype® and intends to follow a focused strategy to maximize impact on selected markets in the most cost-effective way, aiming to achieve recurring sales and prove the business model in different geographical markets. An important aspect, in addition to the focused sales efforts, is to simultaneously strengthen the scientific foundation through local validation studies. Local validation studies are often a prerequisite for doctors and healthcare institutions to adopt a new product. In addition to the Nordic home market, with a focus on Sweden, the Company is initially focusing its resources on the American, Spanish, Italian, and Taiwanese markets. A more detailed description of these focus markets can be found below in priority order.

Over the past two years, the Company has systematically worked on-site in various countries to map and evaluate different markets and approaches from a commercial perspective to identify if the following criteria are met or can be met in the near future:

- Clinical acceptance of genetic testing in prostate cancer and confirmed clinical benefit, and
- Market acceptance through clinicians evaluating and beginning to use Prostatype®

USA

Prostatype Genomics has established a subsidiary in the USA, Prostatype Genomics Inc., with the aim of systematically addressing the U.S. market. A key element of this strategy is to have competent and experienced staff in place with a broad network of urologists to facilitate an accelerated launch. In early 2023, the Company hired Steven Gaal as President of Prostatype Genomics Inc. and Professor Gerald Andriole as Chief Medical Officer. Steven Gaal has over 18 years of experience in leadership positions within the sales of cancer diagnostic tools and services, including prostate cancer. He has held senior roles at USLABS, P4Diagnostix, and most recently SkylineDx. As Sales Director at MDxHealth, Steven Gaal played a crucial role in launching ConfirmMDx and SelectMDx for prostate cancer to U.S.-based urologists. Professor Gerald Andriole comes from his position as a professor at the Department of Urology and Director of the Brady Urological Institute at Johns Hopkins University and has contributed more than 450 peer-reviewed publications. Professor Andriole has also been chair of the prostate committee for the National Cancer Institute's Prostate, Lung, Colorectal, and Ovarian Cancer Screening Study (PLCO), chair of the Prostate Committee for the Society of Urologic Oncology Clinical Trials Consortium, and chair of the steering committee for the REDUCE International Prostate Cancer Prevention Trial. The Company believes that recruiting senior individuals to the management team will facilitate the commercial establishment in the U.S.

To launch a medical device in the U.S., the product must either be approved by the U.S. Food and Drug Administration (FDA), which involves a lengthy process, or be offered through a so-called CLIA laboratory (Clinical Laboratory Improvement Amendments), which means that a laboratory holds a CLIA certification. Such a party can then offer tests (such as Prostatype®) that are not FDA-approved. In the U.S., the Company has established Prostatype® in collaboration with the CLIA-certified laboratory PacificDx. Prostatype Genomics Inc. holds and owns the CLIA license, which is commercially significant as the entire reimbursement goes directly to the Company. Prostatype® is provided as a Laboratory-Developed Test (LDT) and is already commercially available and in clinical use on the U.S. market.

By introducing Prostatype® in the U.S., the Company has avoided the time-consuming and costly process that a direct FDA application would have entailed. There are three similar biomarkers established on the U.S. market; however, they measure gene expression focusing on proliferating stem cells, whereas Prostatype® measures gene expression focusing on embryonic stem cells. All similar products hold CLIA certification and are offered on the market as LDT tests, consistent with how Prostatype® will be launched.

The U.S. market is far ahead of markets like Europe in terms of knowledge and use of genetic testing for prostate cancer. Prostatype® has been available for sale in the U.S. since June 2024 and has started being used clinically on patients there. To gain significant market share in the U.S., it is essential for the Company to obtain Medicare approval, which would mean Prostatype® would receive reimbursement from Medicare, expected to be achieved in 2025. The Company believes that once Prostatype® receives reimbursement, the penetration rate in the U.S. launch will be significantly higher than it has been in Europe. One of the requirements to obtain reimbursement from entities like Medicare is for the Company to present data demonstrating the same or better clinical benefits as similar products show in the U.S. population. For this reason, the Company is conducting an ongoing validation study in collaboration with Veteran Affairs, aiming to present additional data on African American patients. Preliminary data from this study shows performance in line with the results the Company has already shown in European and Asian studies. The data also shows that there is no statistical difference in Prostatype® performance across ethnic groups. The goal is for the study results to be published in a suitable scientific journal in 2025. The current reimbursement for similar tests from entities such as Medicare is approximately $3,873 per test. However, the Company intends to carry out a soft launch even before potential reimbursement is achieved. Prostatype® will then be available, but payment will need to be arranged by the patient or another party, such as an employer or insurance company.

A validation study with Prostatype® in the U.S. is being conducted in collaboration with Veteran Affairs, the U.S. insurance provider for military personnel. The study includes a diverse patient population, with a large proportion of African American patients, and has a long follow-up period. Preliminary results for the study's primary endpoints are expected to be available soon. With the study being conducted in the U.S., the Company's assessment is that after obtaining Medicare approval, Prostatype® will gain even greater attractiveness, enabling the Company to expand its operations either through partnerships or a gradual launch under its own management. Potential collaborations with larger players in the industry on a global or regional basis, either through ownership stakes or commercial collaborations, may thus become relevant. The Company maintains ongoing contacts with several stakeholders regarding collaborations at local, regional, and global levels.

Spain

In March 2023, Prostatype Genomics initiated a collaboration with Spanish Eurofins Megalab. Eurofins Megalab operates in clinical analysis within the Spanish laboratory market and is part of Eurofins, one of the world's largest laboratory groups with operations in Europe, the U.S., Asia, and Latin America. The agreement means that Eurofins Megalab manages all stages of the laboratory process required to analyze the Prostatype® test in the Spanish and Portuguese markets. Eurofins Megalab has an extensive network of urologists and operates in over 50 private hospitals in Spain. As part of the collaboration and preparation for the launch, the Company conducted a study with nearly 100 patients in collaboration with seven Spanish hospitals and the Spanish National Urology Association. The final results of the study showed that the treatment plan could have been modified for 39% of the patients if Prostatype® had been used as a basis for the diagnosis. Sales have already begun in Spain. Through the study, several Spanish urologists have gained direct experience with Prostatype®, which both facilitates subsequent clinical implementation and could be used as a basis for reimbursement via private or public healthcare providers. The study has been approved for publication in a scientific journal and will be made public in the near future. Furthermore, the Company is currently working on a Spanish health economic study to further strengthen the commercial and economic incentives.

Prostatype Genomics has identified Spain as one of its focus markets in Europe. The number of new cases of prostate cancer in the country exceeds 33,000 annually, and there is significant awareness among both urologists and the Spanish National Urology Association that improved risk classification of diagnosed prostate cancer could lead to both significantly improved quality of life for many patients and reduced waiting times in healthcare, as well as substantial cost savings.

Italy

In December 2024, Prostatype Genomics announced that it had received its largest order to date, valued at SEK 1.7 million, from University Hospital Policlinico Tor Vergata in Rome, Italy. The order included a low three-digit number of Prostatype® test kits. This order deepens Prostatype Genomics' collaboration with Professor Pierluigi Bove, a leading Italian urologist with over 150 published scientific articles, and Professor Giuseppe Novelli, a medical genetics professor with around 700 published scientific articles. University Hospital Policlinico Tor Vergata in Rome is a leading Italian urology clinic that handles a significant number of new prostate cancer cases in Italy each year. Prostatype Genomics is now actively working towards the next phase of commercialization, which involves continuing to lay the foundation for a long-term commercial and scientific partnership with the university hospital and expanding the use of Prostatype® to other parties.

Nordics

In the Nordic region, Prostatype® is marketed independently through the Company's experienced sales manager. Prostatype Genomics believes that direct sales (private urologists, private hospitals, insurance companies, and out-of-pocket patients) is initially the most effective approach until Prostatype is included in the public insurance system. Currently, 15 private urology clinics in Sweden offer Prostatype®, and the Company expects to add more clinics throughout 2025. Sales in Sweden are primarily from the private market, although some sales are also expected from public hospitals. The Company has also started small-scale commercial activities in Norway and has initiated a collaboration with Kreftklinken in Oslo.

Prostatype Genomics is currently conducting a retrospective study in collaboration with the Uppsala University Hospital, which includes patients diagnosed more than 30 years ago. Interim data from the study was recently presented at the AUA (American Urology Association) Annual Meeting in Texas, USA. The study is in its final phase, and results are expected to be communicated in the second half of 2025.

Taiwan

The Company conducted a validation study in Taiwan during 2023-2024. The study is currently undergoing scientific review by a scientific journal and is expected to be published in the coming quarters. Taiwan has one of the most advanced healthcare systems in the world and serves as a strong reference for other healthcare systems in Asia. The study once again demonstrated a significantly superior performance of Prostatype® in predicting prostate cancer-specific mortality compared to the standard risk classification systems currently used in Taiwan, such as NCCN® (National Comprehensive Cancer Network), and other clinical parameters like PSA levels.

Based on the promising results from Stage 1 and Stage 2 of the validation study, Prostatype Genomics has already initiated the regulatory approval process with the Taiwan Food & Drug Administration ("TFDA"), which the Company deems necessary to fully launch the product on the Taiwanese market and to obtain subsidies. Sales in Taiwan began in 2022. The Company has initiated a collaboration with a local distributor to continue the sale of Prostatype® in Taiwan.

Other countries

Prostatype Genomics has been the first to launch a prognostic biomarker for the treatment of confirmed prostate cancer in many countries in Europe. Through this, the Company has mapped logistical challenges and opportunities, which vary from country to country. A large part of the European market and healthcare systems are still immature in the sense that national public reimbursement systems for the type of genetic test represented by Prostatype® do not yet exist, meaning that patients have to pay for the test themselves. However, the Company has identified several countries in Europe where there are various reimbursement systems on a regional or hospital-specific basis funded by public budgets or insurance companies. Based on these experiences, the Company has – in addition to the Nordic countries and Spain – chosen to initially establish a presence in Italy.

Collaborations

In 2023 and 2024, the Company entered into around fifteen collaborations with private urology clinics in Sweden, allowing patients and doctors access to Prostatype® and better decision-making support when choosing treatment for prostate cancer. The agreements are ongoing, with new clinics continuously being added. As previously mentioned, the Company has also entered into partnership agreements with Eurofins Megalab in Spain and Eurofins Genoma Lab in Italy. Discussions are ongoing with other stakeholders in additional countries.

Business model

Prostatype Genomics' business model and concept involve manufacturing, marketing, and selling the Prostatype® Test System as a prognostic package. This package consists of the Prostatype® RTqPCR kit, a patient database, evaluation software, and the associated P-score.

Execution of the Test

Currently, the laboratory test for Prostatype® is conducted in Prostatype Genomics' own clinical service laboratory as well as in certified laboratories across Europe, Asia, and the USA. The test is designed for use on existing laboratory platforms, allowing it to be performed locally in laboratories. The database and associated algorithm are offered as a cloud-based solution. Each Prostatype® test includes a unique code that is required to access the database and retrieve the P-score from the test. The code is valid only for one test and cannot be duplicated. The cloud-based service meets all CyberSecurity requirements.

Manufacturing

Prostatype Genomics' contract manufacturer (CMO) for the production of Prostatype® is Minerva Biolabs GmbH in Berlin, Germany.

Product Development

Prostatype Genomics is continuously working on product development. From a laboratory perspective, the test is based on standard PCR technology, which ensures a well-established and stable method. The main area of focus within product development is the ongoing work with the Company's AI and machine learning, aiming to continuously improve the algorithms for various endpoints relevant to prostate cancer, particularly in the U.S. market. The use of 'big data' is intended to ensure the product's competitive performance and ensure the Company is well-prepared for any new clinical angles that healthcare systems may find relevant.

Margins

According to the Company's assessment, the production is internationally scalable due to the development of the software and cloud-based solution. The product is associated with a premium price and a high gross margin, which for Prostatype Genomics is expected to average around 97%. The average sales price for the test is estimated to range between SEK 8,000 and SEK 15,000 depending on the geographic market. In the U.S., the sales price at the time of this prospectus is USD 3,873 per test. The estimated price for the end-user is approximately SEK 20,000–40,000 per test depending on the geographic market and reimbursement systems. Distributor margins are estimated to be around 50% depending on the geographic market.

IVDR Certification

In November 2024, Prostatype Genomics received certification under the EU In Vitro Diagnostic Regulation (IVDR) following an extensive evaluation process by the Company's notified body, TÜV SÜD. The certification signifies that the Company's operations within prognostic genetic testing for diagnosed prostate cancer meet high standards for safety, quality, and performance, marking a significant regulatory milestone.

Studies

Prostatype Genomics has conducted several clinical studies in various countries and has additional ongoing national validation studies in different regions. The validation studies are primarily conducted for marketing purposes, to build a network of experts (Key Opinion Leaders, KOLs), clinicians, and to facilitate the process of gaining approval for reimbursement within national systems. Each validation study typically involves 50-100 patients. A selection of the Company's completed, ongoing, and upcoming studies is described in more detail below.

Conducted studies

Validation study at the University Hospital of Skåne

In a validation study at Skåne University Hospital, where Associate Professor Göran Ahlgren was the lead researcher, it was shown that 36.7% of patients whose prostate cancer had been categorized as intermediate risk could be reclassified to low risk. Approximately 42% of patients whose prostate cancer had been categorized as high risk with existing methods could be reclassified to low (10.5%) and intermediate (31.5%) risk. None of the patients whose cancer was graded with a P-score in the low or intermediate categories died as a result of prostate cancer, further strengthening the prognostic value and reliability of the P-score. The choice of treatment strategy is closely linked to the associated risk group. As a result, a decision on whether to operate on prostate cancer or not may differ based on the outcome of the P-score compared to the original assessment. The results of the study were presented at the European Association of Urology in 2020 and at the American Urology Congress in 2021. The study was published in the internationally recognized journal 'Prostate' in 2023.

	P-score	Patients	%	PCA-death
Low	Low	10	70.0	
	Intermediary	3	23.0	
	High	0	0.0	
Intermediary	Low	40	36.7	
	Intermediary	60	55.0	
	High	9	8.3	

	Low	13	10.5	
High	Intermediary	39	31.5	
	High	72	58.0	16
	Low	1	1.4	
Locally advanced	Intermediary	4	5.8	
	High	64	92.8	17

The table shows the results from the validation study conducted at Skåne University Hospital during 2021/2022.

Clinical study at Akademiska Hospital in Uppsala

The Company conducted a clinical study with Prostatype® at Akademiska Hospital in Uppsala during the period 2021–2022, led by Associate Professor Michael Häggman at the Urology Clinic. The purpose of the study was to determine whether the results from the use of Prostatype® before treatment decisions for patients with prostate cancer correlate with the actual aggressiveness of the tumor. The first question was whether Prostatype® and its algorithm, P-score, correlate in fusion-guided biopsies (tissue samples) in relation to surgically removed prostates, so-called prostatectomies. The second question concerned the correlation in gene expression in the actual index tumor in relation to other cancer areas in the prostate.

The results show a high degree of correlation in P-score values (0.83 – 0.84) for both questions, which are further underscored by the statistical significance for both (p <0.0001). This means that the test results from the tissue samples with Prostatype® provide the indication needed to more confidently determine the next step in the patient's treatment. The results exceeded the Company's high expectations, and the study has generated interest and was presented at one of the world's largest urology conferences, the American Urology Association ("AUA") in New Orleans, USA, during the spring of 2022.

Pilot study in China

Prostatype Genomics, in collaboration with Nanjing Gulou Hospital in China, conducted a pilot study with Prostatype®. The purpose of the study was to confirm that the Company's P-score works as expected in the Asian population. The study indicates that the clinical performance of Prostatype® in the East Asian population aligns with the results previously shown in several studies within Caucasian populations. A total of over 100 patients participated in the pilot study. All patients who either died from prostate cancer or developed metastases were identified as 'high-risk patients' according to the Prostatype® P-score, indicating that Prostatype is a valuable decision support tool also in the Asian population. The study was selected for presentation at the Chinese Urological Association's National Congress in 2022.

Validation study in Taiwan

In October 2023, Prostatype Genomics presented the results of a validation study conducted at Chang Gung Memorial Hospital in Taipei, Taiwan. The purpose of the study was to investigate whether Taiwanese prostate cancer patients could benefit from using Prostatype to assess aggressiveness and, consequently, treatment decisions, as well as to build a network of key individuals and clinicians to facilitate the process of being approved for national reimbursement systems. The study involved 148 patients and once again demonstrated a significantly superior performance of Prostatype® in predicting prostate cancer-specific mortality compared to the standard risk classification systems currently used in Taiwan, such as NCCN® (National Comprehensive Cancer Network) and clinical parameters like PSA levels. The study shows that Prostatype® plays a key role in reducing both over- and under-treatment of prostate cancer patients in Taiwan as well. This study is one of very few studies involving genetic markers in prostate cancer conducted in Asia. It contributes to strengthening the knowledge of the benefits of prognostic genetic markers for prostate cancer patients in Asia and creates opportunities for Prostatype Genomics to establish itself in new markets in Asia, with very promising potential. The study is expected to be published in a scientific journal in 2025.

Validation study in Spain

Prostatype Genomics' retrospective multicenter study with Prostatype® in Spain, which concluded with positive results in April 2024, included approximately 140 patients from a total of seven hospitals and was coordinated by the Spanish National Urological Association. The final results show that the treatment plan could have been modified for 39% of the patients if Prostatype® had been used as the basis at the time of diagnosis. In addition to the fact that the use of Prostatype® at the time of diagnosis led to a reclassification of 39% of the patients, the study showed that Prostatype® can predict progression, i.e., predict which patients need immediate curative treatment at the time of diagnosis and are therefore not suitable for active monitoring, as well as confirm the cases where it may be

appropriate to postpone curative treatment for certain men with low-risk prostate cancer. Based on the very positive results, the Spanish Urological Association and Prostatype Genomics decided to continue the study and make it more comprehensive. The study has been completed with positive results and has been published in a scientific journal during the second quarter of 2025.

Ongoing studies

Study in Sweden

The study is being conducted in collaboration with the Academic University Hospital in Uppsala, with up to 30 years of follow-up time. A total of approximately 500 patients are included in the study, of which around 180 patients have already been analyzed. Previously, Prostatype completed studies with about ten years of follow-up time. The study allows the Company to predict the risk of death from prostate cancer with even greater accuracy in the future, as well as extend the follow-up period to 15-20 years. Interim results, communicated through a press release from the Company in April 2024, have shown very good accuracy for Prostatype® even after a full 20 years of follow-up post-diagnosis. None of the analyzed patients classified as low risk by Prostatype® died from their prostate cancer during up to 20 years of follow-up.

Study in the USA

The study with Prostatype® in the USA includes approximately 200 prostate cancer patients with a broad range of ethnicities. The tissue samples come from Veterans Affairs, and the study is officially conducted by Veterans Affairs with Professor Stephen Freedland as the study leader. Veterans Affairs is a government organization that provides healthcare to Americans who have served in the military. After Medicare, which covers about 60% of the population with health insurance in the US, Veterans Affairs is one of the largest insurance systems, covering around 6% of the insured.

The Company communicated in March 2025 that preliminary results once again showed impressive performance for Prostatype®, aligning well with the results observed in European and Asian studies. Additionally, the preliminary analysis indicates that there is no statistical difference in the performance of Prostatype® between African Americans and Caucasians, which is of great importance, especially for the US market. The data analysis is expected to be completed shortly, with the goal of presenting and publishing the final results of the study in a relevant scientific journal during 2025.

Upcoming studies

Prostatype Genomics plans for additional validation studies in both the USA and Euroupe.

Patents and other intellectual property rights

Prostatype Genomics is the exclusive owner of all research and development, intellectual property rights, and patents. The Company has been granted trademark protection for Prostatype® in Europe and holds six approved patents as of the date of the prospectus' publication. The patents cover the use of the three genes that the Company uses to predict prostate cancer. All patents are described in the table below.

Patent number	Status	Country	Valid until
2771481	Godkänt	Europa (EPO)	2032-10-24
ZL201280064273.1	Godkänt	Kina	2032-10-24
HK1197686	Godkänt	Hongkong	2032-10-24
6049739	Godkänt	Japan	2032-10-24
9790555	Godkänt	USA	2034-03-21
2852020	Godkänt	Kanada	2032-10-24

GENERAL COMPANY INFORMATION

The Company's name (and commercial designation) is Prostatype Genomics AB (publ). The Company's registration number is 556726-0285. The Company is a Swedish public limited company that was established on February 5, 2007, and registered with the Swedish Companies Registration Office on March 12, 2007. The Company is regulated by, and operates in accordance with, the Swedish Companies Act (2005:551). The Company's Legal Entity Identifier (LEI) is 549300JO6MPCGPVHVU91. The Company's registered office is located in the municipality of Stockholm, at Augustendalsvägen 20, 131 52 Nacka Strand. The Company can be contacted via its website at www.prostatypegenomics.com, email info@prostatypegenomics.com, or by phone at +46 (0)8-20 87 00. Please note that the

information on the website is not included in the prospectus unless it is incorporated into the prospectus by reference. See the section 'Documents Incorporated by Reference.'

Organizational structure

The Company is the parent company of the group, which, in addition to Prostatype Genomics, consists of the wholly-owned subsidiary Prostatype Genomics Inc., which serves as a sales company for the American market. The board assesses that Prostatype Genomics is not dependent on the American subsidiary but that it facilitates the Company's establishment and sales in the U.S. market. As of the date of this prospectus, the number of employees in the Company is four (4) persons, and the number of employees in the subsidiary is two (2) persons.

Trends

It is the board's assessment that there are no significant known development trends when it comes to production, sales, sales prices and stock from the from the end of the last financial year until the date of the prospectus.

Future prospects and challenges

Healthcare in several countries is financed by insurance, public or private. This means that one of the Company's challenges is to ensure that Prostatype Genomics' product is approved for reimbursement by insurance companies. The Company's primary focus is on obtaining reimbursement in the US market and is currently conducting a complementary validation study. For the same reason, the Company has completed a validation study in Spain and recently completed a study in Taiwan, as each country places great importance on local data. During 2023 and 2024, the Company has investigated various geographic markets and their conditions for a rapid establishment of Prostatype, concluding that the aforementioned target markets are best suited, both in Europe, Asia and the US.

Once a sufficient amount of data has been collected, it is necessary to establish good relationships with urologists, as it is the urologists who will then recommend the Company's test as part of the treatment decision in cases of confirmed prostate cancer. Prostatype Genomics is actively working to establish networks with so-called Key Opinion Leaders (KOL) in selected geographic markets with a primary focus on the American market.

The Company believes that they are well positioned to meet the challenges, not least because the Company has already established relationships with reputable urologists.

The Company is at the beginning of the commercialization process and is currently focusing on a few selected primary geographic markets, of which the American market is the most significant. Conducting validation studies and obtaining reimbursement are fundamental in this process. The Company's assessment is that if these two steps are successfully implemented, sales may increase significantly in the future, which places both operational and financial demands on the Company. Launching a product involves significant investments in the sales organization and increased tied-up working capital. Although the Company believes that competition is lower in Europe than in the US, the Company believes that the majority of the Company's future revenues will be generated in the US due to a combination of greater market potential and a longer-standing acceptance and clinical tradition of using genetic tests of the type provided by Prostatype Genomics. An important parameter is the fact that prognostic biomarkers for use in confirmed prostate cancer are reimbursed by US insurance systems, unlike in Europe and Asia.

Investments

The Company has not made any significant investments since the end of the last financial period.

Ongoing investments and commitments to future investments

As of the date of publication of the prospectus, the Company does not have any significant ongoing investments or investments for which firm commitments have already been made.

Financing of the Company's operations

Prostatype Genomics intends to continue to finance the Company's operations, investment and working capital needs through net proceeds from the Offering and any sales proceeds. In the event that the Company does not obtain sufficient proceeds from the Rights Issue to finance the Company's operations, investment and working capital needs during the next twelve months (counted from the date of this prospectus), additional external financing may be required.

Significant changes to the Company's debt and financing structure since the Company's last financial report

Since December 31, 2024, the Company has raised a bridge loan of approximately SEK 5 million, in order to finance the capital requirement until the Rights Issue is completed. The bridge loan is intended to be repaid with funds from the Rights Issue. The loan was raised in April 2025, with a commitment fee of 5 percent, and carries an interest rate of 1.5 percent per commenced 30-day period.

WORKING CAPITAL STATEMENT

The existing working capital is, in the opinion of the Board, insufficient to operate the current operations for twelve months from the date of this prospectus. The Company estimates that the deficit will arise in June 2025 and with the current business plan, the need accumulates to a total of SEK 40 million for the coming twelve-month period. The upcoming initial part of the Rights Issue is intended to and is expected to provide the Company with capital to meet the Company's needs up to and including Q4 2025, assuming full subscription. In addition, the Company may be provided with additional capital through the series TO5 warrants attached to the Rights Issue. In order to finance the Company's plans for at least twelve months from the date of this prospectus, it is required that the Company be provided with a total of approximately SEK 40 million, after issue costs, through the initial part of the Rights Issue and series TO5 warrants together or combined with other financing.

In order to provide the Company with working capital and finance its growth plans, Prostatype Genomics is now carrying out the Rights Issue, which, if fully subscribed, may initially provide the Company with a maximum of approximately SEK 27.3 million before issue costs. Prostatype Genomics has received subscription commitments via written agreements corresponding to approximately SEK 3.4 million, corresponding to approximately 12.6 percent of the initial issue volume. In addition, the Company has received, via written agreements, bottom guarantee commitments of approximately SEK 11.7 million, corresponding to approximately 42.9 percent of the issue volume, top guarantee commitments (top-down, from 100 percent down) of approximately SEK 4 million, corresponding to approximately 14.5 percent of the issue volume and top guarantee commitments through a second tranche (top-down, from 85.5 percent down) of SEK 3 million, corresponding to approximately 11 percent of the issue volume. For the bottom guarantee commitment, a guarantee fee of 16 percent will be paid in cash or 20 percent in the form of newly issued units, which will be issued on the same terms and conditions as the Rights Issue. For the top guarantee commitment (top-down, from 85.5 percent down), a guarantee fee of 16 percent will be paid in the form of newly issued units, which will be issued on the same terms and conditions as the Rights Issue. For the top guarantee commitment (top-down, 100 percent down), no guarantee fee will be paid. In total, subscription commitments and guarantee commitments thus correspond to approximately 81 percent of the initial issue volume (equivalent to approximately SEK 22.1 million). However, these commitments and commitments have not been secured via an advance transaction, bank guarantee or similar. The issue costs for the Rights Issue are expected to amount to approximately SEK 4.9 million (of which approximately SEK 1.9 million is attributable to compensation for bottom guarantee commitments, provided that these choose cash compensation).

In the event that one or more underwriters or guarantors fail to fulfill their obligations and/or if the Rights Issue is not subscribed to the extent that the Company's working capital needs for the coming twelve-month period are secured, it is the Board's intention to investigate alternative financing options, such as additional capital raising or financing together with one or more partners, or to conduct operations at a lower rate than estimated, until additional capital can be raised.

RISK FACTORS

An investment in Prostatype Genomics is associated with risks. The risk factors presented below are limited to those risks that are specific and material to Prostatype Genomics and its securities, according to the Company's assessment. The risks are presented in a limited number of categories. For each category, the most material risk factors are stated first according to the issuer's assessment, taking into account the negative effects for the Company and the risk of their realization. Other risk factors are not ranked by materiality or likelihood of the risk occurring. The risk factors include an assessment of the probability of the risk occurring and the extent of its negative impact on the Company. Each risk is assessed with an estimated risk level on a scale of low, medium and high.

RISKS RELATED TO THE COMPANY'S OPERATIONS

Market acceptance

The Company's product, Prostatype®, is in a commercialization phase. At the date of this prospectus, sales of Prostatype® have commenced in Sweden, Spain, the USA, the UK, Norway and Italy. However, there is a risk that sales will not fully meet the Company's objectives and that the product will not be commercially successful. The level of market acceptance and sales of Prostatype® depend largely on whether the product succeeds in gaining recognition among urologists, but also on a number of other factors, such as product characteristics, clinical documentation and results, competing products, distribution channels, availability, price, reimbursement, sales and marketing efforts and that the product is mentioned and noted in various trade journals. If the Company and its product do not receive sufficient attention in the right channels, there is a risk that market acceptance of Prostatype® will be delayed or completely or partially absent.

Since Prostatype® has not yet generated any significant revenues, it is difficult to evaluate the product's sales potential. The product is a support for choosing care for the treatment of prostate cancer and aims to avoid unnecessary surgeries. The Company intends to initially conduct sales to the private healthcare sector (private hospitals, insurance companies and so-called out-of-pocket patients). In order to achieve the market penetration required to achieve the Company's financial goals, a small number of urologists in the target group need to be convinced. The Company considers this to be a realistic expectation. In public healthcare, it takes longer to achieve acceptance and there the Company will be dependent on the national reimbursement systems. The risk is therefore considered to be low in relation to private healthcare and medium in relation to public healthcare. A certain conflict of interest can be considered to exist between the willingness of private healthcare providers to perform surgeries and the Company's ambition to avoid unnecessary surgeries, which risks affecting market acceptance.

Medical technology is generally a market area characterized by global competition, rapid technological development, regulatory requirements and extensive investment requirements. Prostatype Genomics believes that there is currently no product on the European market that is fully equivalent to Prostatype®, but that there are companies in the medical technology sector that could become potential competitors to Prostatype Genomics, for example by developing an equivalent product. If competitors develop products that prove to be better than the Company's, this could have a material adverse effect on the Company's operations, sales, market acceptance, financial position and results, as other Companies may take market share.

The competitive situation in the US market is different, as there are a few US companies that manufacture products that are comparable to Prostatype®. In the US market, the Company may therefore be exposed to competition from existing competitors who want to prevent or hinder the marketing of Prostatype® in various ways, for example by challenging the Company's patents.

Overall, Prostatype Genomics believes that the probability of the risk occurring is medium. The Company further believes that the risk, if it were to materialize, would have a high impact on the Company.

Future capital need

The Company is in an establishment phase where expected cash flows from ongoing operations do not cover planned costs and investments in the form of launching in new markets. Additional financing in the form of loans or other external financing may be needed to finance the working capital requirement to operate the business to the planned extent over the next twelve months. There is a risk that the Company cannot raise additional capital or that such financing cannot be obtained on terms that are favorable to existing shareholders. This could result in the commercialization of Prostatype® being slowed down and the Company being forced to operate the business at a slower pace than desired, which could lead to delayed or non-existent revenues. It could also be significant for the

Company's establishment in the US due to the financing needs of that business. The scenario could have a negative impact on the Company's operations, financial position and results.

Prostatype Genomics assesses the probability of the risk occurring as medium. The Company further assesses that the risk, if realized, would have a medium impact on the Company.

Valuation of assets

The Company's product, Prostatype®, is in a commercialization phase. In addition to the short-term financial risk above, there is, as for all operations, a long-term risk that objectives will not be achieved within the time frame on which the Group's forecasts are based. If sales do not reach the set targets so that the assumed cash flows do not occur at the rate assumed by the Board and management or are postponed further in time, or if other assumptions that have been the basis for the impairment test performed by management were to change in a negative way, this could lead to the intangible assets being written down at a faster rate than planned.

Prostatype Genomics assesses the probability of the risk occurring as low. The Company further assesses that the risk, if it were to materialize, would have a high effect on the Company.

Depencence on key personnel

Prostatype Genomics is a small organization that currently has six permanent employees in the Group. The Company's success is largely dependent on qualified labor and on the extensive expertise and long-term experience within the Company's field of operation held by the employees. Due to the size of the organization and each employee's experience in the field of operation, each employee is considered a key person on whom the Company's operations depend in various respects. One of the Company's main strengths is the internal knowledge of advanced laboratory technology, AI technology and data analysis, which is partly tied to the Company's personnel. If the majority of key people were to leave within a short period of time, it would have a significant negative effect on the Company's ability to conduct the business and to achieve the results the Company seeks. It could also delay the Company's operations and negatively affect its ability to achieve commercial goals.

Prostatype Genomics assesses the probability of the risk occurring as low. The Company further assesses that the risk, if realized, would have a high effect on the Company.

Relevant reimbursement systems

The commercial success of the product is to some extent dependent on reimbursement systems financed or subsidized by national authorities and/or private players. Decisions on inclusion in public healthcare reimbursement systems are made at a national level in the countries where Prostatype® has received marketing approval, which include Sweden, the United Kingdom, Spain, Italy and Germany. In the United States, Prostatype® has also been launched in June 2024 and is a priority market for the Company. Since the criteria on which national authorities and/or private players base their assessments of inclusion in reimbursement systems may change over time, there is a risk that reimbursement for Prostatype® will be less than expected. Reimbursement for Prostatype® via public reimbursement systems differs in different markets as each country in which Prostatype Genomics conducts sales has its own reimbursement system. The risk of lower than expected reimbursement is, however, higher in Europe where, according to the Company, it is more difficult to obtain financing or subsidies for Prostatype® through national reimbursement systems than it is in the US. Prostatype Genomics therefore has a strategy to initially focus on sales directly to the private healthcare sector in Europe, which reduces the dependence on possible inclusion in reimbursement systems. However, there is still a risk that the Company's product is not considered relevant for the above-mentioned reimbursement systems, especially with regard to the level of the reimbursement systems, which would have a negative impact on the Company's operations, financial position and results.

Prostatype Genomics assesses the probability of the risk occurring as medium. The Company further assesses that the risk, if it materializes, would have a medium impact on the Company.

Risks related to partners

Prostatype Genomics has initially managed the sale of Prostatype® to selected urologists in, for example, Sweden, Italy and Spain through its own sales staff. In parallel with this, the Company has also signed agreements with distributors and larger commercial laboratory chains in various countries. At the date of this prospectus, the Company has distributor partners in Spain, Italy and the UK and is currently considering whether the Company should enter into distribution agreements in more countries. A risk with the strategy of entering into distribution agreements is that the Company is unable to find suitable partners, that agreements with partners cannot be entered into on terms that are advantageous to the Company or that partners, if an agreement is entered into, fail to fulfill their

obligations. This could lead to the Company's expected revenue decreasing or not occurring, which would have a negative impact on the Company's operations, financial position and results.

Prostatype Genomics assesses the probability of the risk occurring as low. The Company further assesses that the risk, if realized, would have a medium impact on the Company.

LEGALA AND REGULATORY RISKS

Regulatory risks connecvted to studies and permits

Before medical devices, such as Prostatype®, can be launched on the market, their performance and safety must be ensured, which Prostatype Genomics has done through clinical studies and validation studies in a number of countries. Prostatype Genomics has a strategy of conducting validation studies in each country where sales are intended to be conducted, which does not follow from regulatory requirements but rather from practice. In order to be able to market and sell medical devices, in some cases permits must also be obtained and registration must be made with the relevant authority. Prostatype® is CE marked and approved according to IVDR and the Company has, at the date of this prospectus, permission to sell the product in Europe. The Company has conducted validation studies in Sweden, China, Germany, Spain and Taiwan in order to evaluate the launch of Prostatype® on the Asian market. In the USA, the Company currently has no ambition to secure FDA approval but has launched Prostatype as a so-called LDT product (Laboratory Developed Test), which is a faster and more cost-effective way into the American market, which reduces the financial risk. Competing products in the US are also available as LDT products.

The studies that Prostatype Genomics conducts are associated with uncertainty and risk regarding delays and results. There is a risk that the results of the Company's ongoing and future studies will not be satisfactory and there is a risk that the Company's future products, for safety and/or efficacy reasons, will not be shown to be as good as previous assessments have claimed. Furthermore, there is a risk that the rules and interpretations that currently apply regarding registration and authorization for the Company's product may change in the future, which in such case could affect the Company's ability to meet the requirements of various authorities. Accordingly, changes in rules and interpretations as well as withdrawn authorizations and registrations may also result in delays in market launches in certain markets and risk reducing the Company's growth rate and expected profitability. Overall, this could have a negative impact on the Company's operations, financial position and results.

Prostatype Genomics assesses the probability of the risk occurring as low. The Company further assesses that the risk, if realized, would have a medium impact on the Company.

Intellectual property rights and patent protection and infringement thereof

Prostatype Genomics is dependent on the ability to obtain and defend patents, other intellectual property rights and acquired know-how. Patent protection for medical device companies can be uncertain and involve complex legal and technical issues. Prostatype Genomics has applied for and been granted patents until 2032 in Canada, China, Hong Kong, Japan and Europe (EPO). In the US, the patent is valid until 2034. In the event that future patent applications are not granted, it could negatively affect Prostatype Genomics' operations and financial position. Furthermore, patents usually have to be applied for and maintained in several different jurisdictions and generally have a limited lifespan. There is a risk that the existing and/or future patent portfolio and other intellectual property rights held by the Company will not constitute adequate commercial protection, that other patents dominate over its own patent(s) or that methods or procedures that are patented or patent-pending by others are used. If Prostatype Genomics is forced to defend its patent rights against a competitor, this could entail significant costs, which could negatively affect Prostatype Genomics' operations, results and financial position.

Furthermore, it is always a risk in the type of business that Prostatype Genomics conducts that the Company may infringe or be alleged to infringe patents held by third parties. To date, the Company has not been involved in any patent disputes. It cannot be ruled out that new patents in the field or new discoveries may affect the business. The uncertainty associated with patent protection means that the outcome of such disputes is difficult to predict, but it could result in costly disputes and negative publicity. The effect could be delays or obstacles to continued commercialization of the product and thus also difficulties for the Company to generate revenue.

Prostatype Genomics is also to some extent dependent on know-how and trade secrets, which are not protected by legislation in the same way as intellectual property rights. The Company uses confidentiality agreements and thereby strives for far-reaching protection of sensitive information. However, it is not possible to fully protect itself against unauthorized dissemination of information, which entails

the risk that competitors will gain access to and benefit from the know-how developed by Prostatype Genomics, which could be detrimental to the Company.

Overall, Prostatype Genomics assesses the probability of the risk occurring as low. The Company further assesses that the risk, if it materializes, would have a high impact on the Company.

RISKS RELATED TO THE COMPANY'S SECURITIES AND OWNERS

Dilution in future share issues

The Company may require additional capital to finance its operations through new issues, equity-related securities or convertible debt instruments, which may result in dilution of existing shareholders' interests in the Company and may also affect the price of the shares. There is also a risk that additional financing on acceptable terms will not be available to the Company when required, or will not be available at all. If these risks were to materialize, they could have a material adverse effect on shareholders' financial interests, investors' invested capital and/or the price of the shares.

Prostatype Genomics assesses that the probability of the risk occurring is medium and that the impact of the risk, if it were to materialize, would be medium.

Shareprice development

There is no guarantee that the share price of Prostatype Genomics will develop positively and there is a risk that investors in the Company will not, in whole or in part, receive back the invested capital. Prostatype Genomics is a growth company that is currently conducting sales on a limited scale. The Company's share price may develop negatively as a result of, for example, market expansion and sales growth taking longer than expected. A negative share price development may also be based on circumstances such as stricter legal requirements for medical devices, difficulties in including Prostatype® in relevant reimbursement systems and possible challenges in financing the Company's operations and growth. Since October 27, 2020, through May 8, 2025, the Company's share has fluctuated between a high of approximately SEK 16.60 and a low of approximately SEK 0.02 [it is noted that the Company carried out a share reverse split in 2024, 1,000:1, and that historical prices above have not been restated to take this reverse split into account]. There is a risk that the Company's share price may fluctuate significantly in the future, primarily as a result of large changes in buying and selling volumes that are not necessarily related to Prostatype Genomics' underlying value. The Company's share price may be subject to extreme price and volume fluctuations that are not related to or proportionate to the operational outcome of Prostatype Genomics.

Prostatype Genomics assesses that the probability of the risk occurring is low and that the effect of the risk, if realized, would be medium.

Shareholders with significant incluence

Individuals in both the board of directors and management own shares in Prostatype Genomics. Management and the board of directors, together with major shareholders, have the opportunity to exercise significant influence over matters referred to the Company's shareholders for approval at the general meeting, including the election of board members, the issuance of additional shares or share-related securities that may result in dilution for existing shareholders, decisions on possible dividends and future acquisitions or sales of all or parts of the business. In addition, the principal shareholders have significant influence over the election of members of the Company's board of directors and thus indirectly also the Company's senior executives.

There is a risk that the above may be to the detriment of other shareholders who may have interests other than the principal shareholders. In addition to applying the protective rules that follow from law, such as the minority protection rules of public limited companies, Prostatype Genomics has no opportunity to take measures to ensure that this influence is not abused. There is also a risk that the Company's share price will decline significantly if there is a large-scale sale of shares in the Company, especially if such sale is carried out by board members, senior executives or major shareholders. In the event that a sale is carried out by one or more share-owning board members, major shareholders and/or senior executives, this may have a significant impact on the price development. If a sale is carried out by shareholders with significant influence, this may also lead to a belief among other shareholders that the selling shareholders have a weakening faith in the Company and its future prospects.

The Company assesses that the potential probability of the risk occurring is low and that the effect of the risk, if it is realized, would be medium.

Risks related to unsecured subscription commitments and guarantee commitments

A number of existing shareholders and external investors have entered into subscription commitments and guarantee commitments in the Offering corresponding to a total of approximately SEK 22.1 million. However, these commitments are not secured via advance transaction, bank guarantee or similar, which means that there is a risk that these commitments will not be met. The agreements also contain conditions for completion and provisions on termination. If any of these conditions are not met, there is a risk that the commitments will not be met. Accordingly, a breach or termination of any of the agreements could have a material adverse effect on the Company's ability to successfully complete the Offering. The risk of non-payment of the issue, in whole or in part, could have a negative impact on the Company's implementation of planned activities. Furthermore, it could impact future earnings, increase future costs or otherwise negatively affect the Company's operations, results and financial position.

The Company assesses that the potential probability of the risk occurring is low and that the impact of the risk, if it were to materialize, would be high.

THIS IS A TRANSLATION OF THE ORIGINAL VERSION IN SWEDISH FOR INFORMATION PURPOSES ONLY.
IN CASE OF A DISCREPANCY, THE SWEDISH ORIGINAL WILL PREVAIL.

TERMS FOR THE SECURITIES

GENERAL INFORMATION

The shares in Prostatype Genomics have been issued in accordance with the Swedish Companies Act (2005:551) and the rights attached to shares issued by the Company, including the rights provided for in the articles of association, may only be adjusted in accordance with the procedures set out in the said Act. Prostatype Genomics has one class of shares and all shares have the same priority in the event of insolvency. The shares are denominated in SEK. All shares are fully paid and freely transferable and have ISIN code SE0023261532.

CERTAIN RIGHTS ASSOCIATED WITH THE SHARES

Shareholders' rights regarding dividend distribution, voting rights, preferential rights when subscribing for new shares, etc. are governed partly by Prostatype Genomics' articles of association, which are available via the Company's website, and partly by the Swedish Companies Act (2005:551).

Voting rights at general meetings

At the Annual General Meeting, shares carry a voting value of 1 and each voting member may vote for their full number of shares without restriction. All shares give shareholders the same preferential rights in the issue of warrants and convertibles to the number of shares they own.

Preferential rights to new shares, etc.

If the Company issues new shares, warrants or convertibles in a cash issue or a set-off issue, the shareholders generally have preferential rights to subscribe for such securities in proportion to the number of shares held prior to the issue.

Right to dividends, share of the Company's profits and proceeds upon liquidation

All shares in the Company carry equal rights to dividends and to the Company's assets and any surplus in the event of winding up through liquidation or bankruptcy. The new shares carry the right to dividends for the first time on the first record date for dividends that falls after the new shares have been registered with the Swedish Companies Registration Office. The new shares have the same right to dividends as the existing shares.

Decisions on dividends are made by the general meeting and payment is arranged by Euroclear Sweden AB. The right to dividends accrues to those who are registered as shareholders in the share register maintained by Euroclear Sweden AB on the record date for dividends decided by the general meeting. Dividends, to the extent decided upon, are normally paid as a cash amount per share through Euroclear Sweden AB, but may also consist of other things than cash. If shareholders cannot be reached through Euroclear Sweden AB, the shareholder's claim against the Company regarding the dividend amount remains and such claim is subject to a ten-year limitation period. In the event of limitation, the dividend amount accrues to the Company. The Company does not apply any restrictions or special procedures regarding cash dividends to shareholders residing outside Sweden. With the exception of any restrictions resulting from banking and clearing systems, payment is made in the same way as for shareholders residing in Sweden. However, shareholders who are not tax residents in Sweden are normally subject to Swedish withholding tax.

PUBLIC TAKEOVER BIDS AND COMPULSORY REDEMPTIONS

In the event that a public takeover offer is made for the shares in Prostatype Genomics, the Takeover Rules (rules concerning public takeover offers for shares in Swedish limited liability companies whose shares are traded on certain trading platforms) administered by the Swedish Stock Market Self-Regulation Committee will apply to such offer, as of the date of the prospectus. If the board of directors or the CEO of Prostatype Genomics, based on information originating from the person intending to make a public takeover offer for shares in the Company, has reasonable grounds to believe that such an offer is imminent, or if such an offer has been made, Prostatype Genomics may, under the Takeover Rules, only take measures that are likely to impair the conditions for making or implementing the offer, following a resolution of the general meeting. However, this does not prevent the Company from seeking alternative offers.

A takeover offer may apply to all or part of the shares in a company, and may either be voluntary through a public takeover offer or mandatory through a so-called mandatory bid. A mandatory bid arises when an individual shareholder, alone or together with related parties, achieves a holding that represents at least 30 percent or more of the votes in a company. Under a public takeover offer, shareholders are free to decide whether they wish to sell their shares in the public takeover offer. After a public takeover offer, the

person who made the offer may, under certain conditions, be entitled to redeem the remaining shareholders' shares in accordance with the rules on compulsory redemption in Chapter 22 of the Swedish Companies Act (2005:551). Such compulsory redemption may occur if the bidder achieves more than 90 percent of the shares in the Company. Correspondingly, a shareholder whose shares may be subject to redemption has the right to such redemption by the majority shareholder. This process is part of the minority protection which aims to create fair treatment of all shareholders, where shareholders who are forced to dispose of their shares shall receive fair compensation.

The shares newly issued in the Rights Issue are not subject to any offer made as a result of a mandatory bid, redemption right or redemption obligation. Nor have any public takeover offers been made regarding the shares during the current or previous financial year.

THE RIGHTS ISSUE

The Annual General Meeting on 15 May 2025 resolved to approve the Board of Directors' decision of 15 April 2025 to implement the Rights Issue. New securities issued in connection with the Rights Issue will be issued in accordance with Swedish law and the currency is in Swedish kronor (SEK). The subscription period for the Offering runs from 21 May 2025 to 4 June 2025. New securities issued in connection with the Rights Issue are expected to be registered with the Swedish Companies Registration Office in mid-June 2025. The stated date for registration is preliminary and may be subject to change.

AUTHORIZATIONS

At the Annual General Meeting on 15 May 2025, the meeting resolved to authorize the Board of Directors to, on one or more occasions during the period until the next Annual General Meeting, decide to issue shares, warrants and/or convertible loans (or combinations thereof, so-called units). If the Board of Directors exercises the authorization, it may also do so with a deviation from the shareholders' preferential rights and/or with provisions on contributions in kind or set-off. An issue of securities in accordance with this authorization shall be made on market terms. The Board of Directors shall have the right to determine the other terms and conditions for issues pursuant to this authorization and who shall have the right to subscribe for issued securities. The reason why the Board of Directors should be able to decide on an issue with a deviation from shareholders' preferential rights and/or with a provision for contribution in kind or set-off is that the Company should have the opportunity to raise capital for the Company, carry out strategically motivated collaborations or company acquisitions and facilitate the implementation of issues with the aim of strengthening the Company's financial position.

The Annual General Meeting on 15 May 2025 also resolved to authorize the Board of Directors to, on one or more occasions during the period up to 30 July 2025, decide on the issuance of shares and/or warrants (units) through the Extended Offering, which may be used in the event of any oversubscription in the Rights Issue. An issue decided upon with the support of this authorization may be a maximum issue of 1,025,282 units, corresponding to 4,101,128 shares and 3,075,846 warrants of series TO5, which corresponds to approximately 15 percent of the maximum number of units that can be issued in the Rights Issue. An issue decided upon with the support of this authorization may thus increase the Company's share capital by a maximum of SEK 717,697.40, of which a maximum of SEK 410,112.80 is attributable to the initial rights issue and SEK 307,584.60 is attributable to the attached warrants of series TO5.

In addition, the meeting resolved, in connection with the general meeting's approval of the board's decision on the Rights Issue of units, to authorize the board to, on one or more occasions during the period up to the next annual general meeting, decide to increase the Company's share capital within the limits of the articles of association by issuing shares and/or warrants (units). The authorization may only be used to issue units to those who have acted as guarantors in the Rights Issue. If the board exercises the authorization, it may therefore be done with a deviation from the shareholders' preferential rights and with the condition that payment can be made by set-off. The reason for the deviation in such a case is that the Company must be able to fulfill contractual obligations towards the guarantors in the Rights Issue.

CENTRAL SECURITIES DEPOSITORY

The shares in Prostatype Genomics are registered in a central securities depository and financial instruments account management register in accordance with the Act (1998:1479) on Central Securities Depositories and Financial Instruments. This register is maintained by Euroclear Sweden AB, Box 191, SE-101 23 Stockholm. No share certificates have been issued for the Company's shares. All transactions with the Company's shares are carried out electronically through authorized banks and securities custodians. Newly issued shares are registered in the holder's name in electronic form.

TAX ISSUES IN CONNECTION WITH THE RIGHTS ISSUE

Prostatype Genomics is a registered Swedish company with tax liability in Sweden. Investors in the Rights Issue should note that the tax legislation of the investor's Member State and the issuer's country of registration may affect any income from the securities. Investors are advised to consult their independent advisor regarding the tax consequences that may arise in connection with an investment in Prostatype Genomics in connection with the Rights Issue.

THIS IS A TRANSLATION OF THE ORIGINAL VERSION IN SWEDISH FOR INFORMATION PURPOSES ONLY.
IN CASE OF A DISCREPANCY, THE SWEDISH ORIGINAL WILL PREVAIL.

TERMS AND CONDITIONS

PREFERENTIAL RIGHT TO SUBSCRIBE

Those who are registered as shareholders in the share register maintained by Euroclear on behalf of the Company on the record date, 19 May 2025, have preferential rights to subscribe for new units in proportion to the number of shares held on the record date. For each existing share held on the record date, one (1) unit right is obtained. The unit rights entitle the holder to subscribe for new units with preferential rights, whereby one (1) unit right gives the right to subscribe for one (1) new unit. One (1) unit consists of four (4) shares and three (3) warrants of series TO5.

ISSUE VOLUME

The offering comprises a maximum of 6,835,213 units (corresponding to a total of 27,340,852 shares and 20,505,639 attached free-of-charge warrants of series TO5). The total issue amount amounts to a maximum of approximately SEK 27.3 million before issue costs. Through the initial part of the Rights Issue, the share capital may increase by a maximum of SEK 2,734,085.20.

WARRANTS OF SERIES TO5

One (1) TO5 series warrant entitles the holder to subscribe for one (1) newly issued share in the Company and can be exercised during the period from 3 September 2025 to 17 September 2025. Provided that the initial Rights Issue is fully subscribed and that the attached TO5 series warrants are exercised in full, the share capital will increase by an additional SEK 2,050,563.90. The TO5 subscription price shall amount to seventy (70) percent of the average volume-weighted price of the share according to the official price statistics for Nasdaq First North Growth Market during a period of twenty (20) trading days ending before the start of the exercise period. However, a minimum of SEK 0.10 and a maximum of SEK 1.50. The subscription price shall be rounded to the nearest whole öre. The Company will announce the subscription price the day before the first day of the exercise period.

The warrants will be traded from the time the BTU conversion has taken place in Euroclear's system until and including 15 September 2025 and will be traded in Swedish kronor. The warrants have ISIN code SE0024990063. Full terms and conditions for series TO5 warrants are available on the Company's website www.prostatypegenomics.com.

SUBSCRIPTION PRICE

The subscription price is SEK 4.00 per unit, which means that the price per share is set at SEK 1.00. No commission is charged.

RECORD DATE

The record date at Euroclear Sweden AB ("Euroclear") for the right to participate in the Rights Issue is May 19, 2025. The last day for trading in the Company's shares with the right to participate in the Rights Issue is May 15, 2025. The first day for trading in the Company's shares without the right to participate in the Rights Issue is May 16, 2025.

SUBSCRIPTION PERIOD

Subscription of new units supported by unit rights shall take place during the period from 21 May 2025 to 4 June 2025. The Board of Directors of the Company reserves the right to extend the subscription period. Any extension will be announced by the Company through a press release no later than 4 June 2025.

UNIT RIGHTS

For each existing share held on the record date, one (1) unit right is obtained. Unit rights entitle the holder to subscribe for new units with preferential rights, whereby one (1) unit right gives the right to subscribe for one (1) new unit, consisting of four (4) shares and three (3) warrants of series TO5.

TRADING IN UNIT RIGHTS

Trading in unit rights will take place on Nasdaq First North Growth Market during the period from 21 May 2025 to 30 May 2025. Shareholders should contact their bank or other custodian with the necessary permissions to carry out the purchase and sale of unit rights. Unit rights acquired during the above-mentioned trading period give, during the subscription period, the same right to subscribe for units as the unit rights shareholders receive based on their holdings in the Company on the record date.

UNUSED UNIT RIGHTS

Unit rights that have not been sold by 30 May 2025 or used for subscription of units by 4 June 2025 will be cancelled from all VP accounts without compensation. No separate notification will be given when unit rights are cancelled.

THE EXTENDED OFFER

In the event that the Rights Issue is oversubscribed, the Board of Directors may, with the support of authorization from the Annual General Meeting on May 15, 2025, decide on the Extended Offering to issue an additional maximum of 1,025,282 units, corresponding to 4,101,128 shares and 3,075,846 warrants of series TO5. Through the Extended Offering, the Company's share capital may increase by a maximum of SEK 717,697.40, of which SEK 410,112.80 relates to the initial part of the rights issue and SEK 307,584.60 relates to warrants of series TO5. In the issue decision, the Board of Directors shall decide on allocation in accordance with the principles for allocation in the Rights Issue. The right to subscribe for units in the Extended Offering shall accrue to those who subscribe for units in the Rights Issue without receiving full allotment. The Extended Offering may result in a maximum dilution of 10.7 and 5.3 percent, respectively, through the initial issuance of shares and the redemption of warrants of series TO5 for subscription of new shares.

ISSUE STATEMENT AND SUBSCRIPTION

Direct registered shareholders

Shareholders or representatives of shareholders who were registered with Euroclear on the record date of 19 May 2025 will receive a pre-printed issue report with an attached payment notice. Information will be available on Nordic Issuing's website (www.nordic-issuing.se) and on the Company's website (www.prostatypegenomics.com). Those who are included in the list of mortgagees and others kept separately in connection with the share register will not receive any information but will be notified separately. The VP notice reporting the registration of unit rights in the shareholder's VP account was not sent.

SUBSCRIPTION WITH THE SUPPORT OF PREFERENTIAL RIGHTS

Subscription with preferential rights shall be made by simultaneous cash payment no later than June 4, 2025. Subscription by payment shall be made either with the pre-printed payment slip attached to the issue report, or by subscription on Nordic Issuing's platform according to the following two options:

1. Issue statement (preprinted payment slip from Euroclear)
   In the event that all unit rights received on the record date are to be used for subscription, only the pre-printed payment slip should be used as the basis for subscription by cash payment.
2. Subscription through Nordic Issuing with support of unit rights

In the event that a different number of unit rights than that stated in the pre-printed issue report is used for subscription, e.g. by acquiring or selling unit rights, subscription with the support of unit rights shall be made on Nordic Issuing's platform https://minasidor.nordic-issuing.se/ and used as a basis for subscription by cash payment. The shareholder shall log in to the platform and state the number of unit rights that he wishes to exercise, the number of units for which he is subscribing and the amount to be paid. The registration is binding.

INFORMATION TO BANKS/NOMINEES REGARDING SUBSCRIPTION

On the first day of the subscription period, Nordic Issuing will send out an email containing the prospectus, a short summary of the Offering and application forms that all banks/managers can use to subscribe with the support of unit rights for their underlying customers.

Nordic Issuing reserves the right to disregard application forms received by post, as it cannot be guaranteed that they will be received before the last day of the subscription period if they are posted.

NOMINEE-REGISTERED SHAREHOLDERS

Shareholders whose holdings of shares in the Company are registered as nominees with a bank or other nominee will not receive an issue report. Subscription and payment must instead be made in accordance with the instructions from the respective bank or nominee. Please note that when exercising unit rights through a bank or nominee, this should be done early in the subscription period because each bank/nominee may set different deadlines for the last day for subscription.

SUBSCRIPTION WITHOUT THE SUPPORT OF PREFERENTIAL RIGHTS

Subscription of units without preferential rights shall take place during the same period as subscription of units with preferential rights, i.e. from and including 21 May 2025. The Board of Directors of the Company reserves the right to extend the subscription period and the time for payment under any circumstances. Such an extension shall be announced no later than the last day of the subscription period and published by the Company.

Notification of subscription of units without preferential rights shall be made on Nordic Issuing's platform https://minasidor.nordic-issuing.se/.

For nominee-registered shareholders, notification of subscription of units without preferential rights shall be made to the respective nominee and in accordance with instructions from the latter, or if the holding is registered with several nominees, from each of them. In order to be able to invoke subsidiary preferential rights, it is required that the subscription is carried out via the nominee, as otherwise there is no possibility of identifying a specific subscriber who has subscribed for units both with and without the support of unit rights.

Incomplete or incorrectly completed subscriptions may be disregarded. It is only permitted to register a 'Subscription without support of unit rights'. Subscriptions must be made no later than June 4, 2025. Registration is binding.

SUBSCRIPTION FROM ACCOUNTS COVERED BY SPECIFIC RULES

Please note that anyone who has a custody account with specific rules for securities transactions, such as an investment savings account (ISK) or endowment insurance account (KF), must check with the bank or trustee that maintains the account whether acquisition of securities within the framework of the Offer is possible. In such a case, notification must be made in agreement with the bank/trustee that maintains the account.

SUBSCRIPTION OVER EUR 15,000

In the event that the subscription amounts to or exceeds EUR 15,000, a money laundering form must be completed and submitted to Nordic Issuing in accordance with the Act (2017:630) on measures against money laundering and terrorist financing. Please note that Nordic Issuing cannot book out securities, even though payment has been received, until the money laundering control is in Nordic Issuing's possession.

SHAREHOLDERS RESIDING ABROAD

Shareholders residing outside Sweden (but not including shareholders residing in the USA, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore, South Korea, Russia, Belarus or other countries where participation requires additional prospectuses, registration or other measures than those required by Swedish law) and who are entitled to subscribe for units in the Rights Issue, may contact Nordic Issuing for information on subscription and payment.

Due to restrictions in securities legislation in the USA, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore, South Korea, Russia, Belarus or other countries where participation requires additional prospectuses, registration or other measures than those required by Swedish law, no unit rights will be offered to holders with registered addresses in any of these countries. Accordingly, no offer to subscribe for units in the Company is made to shareholders in these countries. Notwithstanding any other provision in this document, the pre-printed issue report or the application forms, the Company reserves the right to permit any person to apply for new securities in the Rights Issue if the Company is satisfied that the transaction in question is exempt from or not subject to the laws or regulations giving rise to the restrictions in question.

ALLOCATION WHEN SUBSCRIBING WITHOUT PREFERENTIAL RIGHTS

In the event that not all units are subscribed for with the support of unit rights, the board of directors shall, within the framework of the maximum amount of the Rights Issue, decide on the distribution of units to others who have subscribed for units without the support of preferential rights. Such distribution shall primarily be made to subscribers who have subscribed for units with the support of unit rights, regardless of whether the subscriber was a shareholder on the record date for the issue or not, and, in the event of oversubscription, pro rata in relation to the number of units subscribed for with the support of unit rights. In the second place, distribution shall be made to those who have subscribed for units without the support of unit rights and, in the event of oversubscription, pro rata in relation to the number of units subscribed for in the notification and, to the extent that allocation cannot be made pro rata, by drawing lots. In the third place, distribution shall be made to guarantors in accordance with the terms of the issued guarantee undertakings.

NOTICE OF ALLOCATION OF UNITS SUBSCRIBED WITHOUT PREFERENTIAL RIGHTS

Notification of any allocation of units, subscribed without preferential rights, will be provided by sending an allocation notification in the form of a settlement note via e-mail. Settlement notes are expected to be sent out as soon as possible after the subscription period has ended and payment must be made no later than four banking days thereafter, according to the instructions on the settlement note. Please note that there is no possibility of withdrawing the amount from the specified deposit account. If payment is not made in a timely manner, units may be transferred to another party. Should the sales price in such a transfer be less than the price according to the Offer, the party who originally received allocation of these units may be liable for all or part of the difference. No notification will be provided to the party who has not received an allocation.

PUBLICATION OF THE OUTCOME OF THE RIGHTS ISSUE

The announcement of the outcome of the Rights Issue is planned for June 5, 2025, or as soon as possible after the subscription period has ended. The Company will publish the outcome of the Rights Issue through a press release.

PAID SUBSCRIBED UNIT (BTU)

Subscription by payment is registered with Euroclear as soon as this can be done, which normally means a few banking days after payment. The directly registered subscriber then receives a VP notification with confirmation that the paid subscribed units (BTU) have been entered in the subscriber's VP account. Subscribed units are recorded as BTU in the VP account until the Rights Issue has been registered with the Swedish Companies Registration Office. Shareholders who have their holdings in custody with a bank or nominee receive information from the respective nominee.

TRADING IN BTU

Trading in BTU will take place on Nasdaq First North Growth Market from 21 May 2025 until the Rights Issue is registered with the Swedish Companies Registration Office. Subscribed units are recorded as BTU in the subscriber's VP account or custody account until the Rights Issue has been registered with the Swedish Companies Registration Office, which is expected to occur in mid-June 2025.

DELIVERY OF SHARES AND WARRANTS

As soon as the Rights Issue has been registered with the Swedish Companies Registration Office, the BTU will be rebooked into shares and warrants without any separate notification from Euroclear. Please note that the issue may be partially registered with the Swedish Companies Registration Office.

TRADING IN THE SHARE

The shares in the Company are listed on Nasdaq First North Growth Market. The shares are traded under the ticker symbol “PROGEN” and have ISIN code SE0023261532. The new securities are admitted to trading in connection with the conversion of BTU into shares and warrants.

RIGHT TO DIVIDEND

The new shares carry the right to dividend for the first time on the first dividend record date that falls after the new shares have been registered with the Swedish Companies Registration Office. The new shares have the same right to dividend as the existing shares.

DILUTION

Through the Rights Issue, the Company's share capital may initially increase by a maximum of SEK 2,734,085.20 through the issue of a maximum of 27,340,852 shares, corresponding to approximately 80 percent of the votes and capital in the Company. The dilution is based on the number of shares issued after the Rights Issue is fully subscribed. Upon full exercise of warrants of series TO5 within the framework of the Rights Issue, the share capital may increase by a maximum of SEK 2,050,563.90, corresponding to an additional approximately 38 percent of the votes and capital in the Company. In the event that the Extended Offering is activated, the Company's share capital may be increased by a maximum of SEK 410,112.80 through the issuance of a maximum of 4,101,128 shares, corresponding to approximately 10.7 percent of the votes and capital in the Company, and by a maximum of SEK 307,584.60 through the issuance of a maximum of 3,075,846 shares, corresponding to approximately 5.3 percent of the votes and capital in the Company, through the exercise of attached warrants of series TO5 in the Extended Offering. If the guarantors who are entitled to compensation choose such compensation in the form of units, the Company's share capital may be increased by a maximum of SEK 282,420.00 through the issue of a maximum of 2,824,200 shares, corresponding to approximately 7.6 percent of the votes and capital in the Company, and by a

maximum of SEK 211,815.00 through a directed issue of a maximum of 2,118,150.00 shares, corresponding to approximately 3.7 percent of the votes and capital in the Company, through the exercise of attached warrants of series TO5.

POSSIBLE RECALCULATION OF SUBSCRIPTION PRICE AND SUBSCRIPTION ENTITLEMENT

The subscription price and the number of shares in the Company that the warrants entitle to subscription may be recalculated in the event of, for example, a bonus issue or new share issue. In the event that recalculation is actualized, the Company will publish more information about this via press release on its website (www.prostatypegenomics.com).

SUBSCRIPTION THAT CONSTITUTES OBLIGATION TO NOTIFY INVESTMENT UNDER THE FDI ACT

The Foreign Direct Investment Screening Act (2023:560) (the "FDI Act") applies to the Company's operations. In the event that subscription for units would result in one of the investor's holdings exceeding the thresholds of 10, 20, 30, 50, 65 or 90 percent of the votes in the Company, the investor is required to report his investment in accordance with the FDI Act. This reporting obligation does not apply if the investor subscribes for units with preferential rights in relation to the number of shares that the investor owns on the record date of 19 May 2025.

INFORMATION ABOUT LEI- AND NCI-NUMBER

According to the securities trading regulations that came into force on 3 January 2018 (Mifid 2/Mifir), all investors need to have a global identification code in order to be able to carry out securities transactions. These requirements mean that legal entities need to apply for registration of a so-called Legal Entity Identifier (LEI) and natural persons need to find out their National Client Identifier (NCI) in order to be able to subscribe for units in the Rights Issue. Please note that it is the legal status of the subscriber that determines whether an LEI code or NCI number is needed, and that Nordic Issuing may be prevented from carrying out the transaction for the person in question if the LEI code or NCI number (as applicable) is not provided. Legal entities that need to obtain an LEI code can contact one of the suppliers available on the market. Instructions for the global LEI system can be found at gleif.org. For natural persons who have only Swedish citizenship, the NCI number consists of the designation "SE" followed by the person's personal identification number. If the person in question has multiple citizenships or something other than Swedish citizenship, the NCI number may be some other type of number. Anyone who intends to subscribe for units in the Rights Issue is encouraged to apply for registration of an LEI code (legal entities) or find out their NCI number (natural persons) in good time in order to have the right to participate in the Rights Issue and/or be able to be allocated units that are subscribed for without the support of unit rights.

MISCELLANEOUS

The Board of the Company does not have the right to cancel, revoke, or temporarily suspend the Offer to subscribe for new shares in the Company in accordance with the terms of the prospectus. In the event that an excessive amount is paid by a subscriber for the subscribed units, Nordic Issuing will ensure that the excess amount is refunded. In such a case, Nordic Issuing will contact the subscriber to obtain bank account details to which the excess amount can be refunded. No interest will be paid on the excess amount. Subscription for new units is irrevocable, and the subscriber cannot cancel or modify a subscription for new units. An incomplete or incorrectly filled-out application/subscription may be disregarded. If the payment for subscribed units is made late, is insufficient, or paid incorrectly, the subscription application may be disregarded, or the subscription may be made for a lower amount. Any paid funds that are not used will be refunded. If multiple applications/subscriptions of the same category are submitted, only the application/subscription that was received last by Nordic Issuing will be considered. Late payments of amounts below SEK 100 will only be refunded upon request.

GUARANTEE UNDERETAKINGS AND SUBSCRIPTION COMMITMENTS

Taken together, the Rights Issue is covered by subscription commitments and guarantee undertakings amounting to approximately SEK 22.1 million, corresponding to 81 percent of the Rights Issue.

Guarantee undertakings

Through agreements entered into with the Company, investors have committed to subscribe for units in the Rights Issue up to a total amount of approximately SEK 18.7 million, corresponding to approximately 68.4 percent of the Rights Issue, in the event that the Rights Issue is not subscribed to approximately 81 percent. The agreements regarding the guarantee undertakings were entered into in April 2025. For the bottom guarantee commitment (which ranges from the subscription commitment up to approximately 55.5 percent), a guarantee compensation of 16 percent in cash or alternatively 20 percent in the form of newly issued units will be paid, which will be issued on the same terms as the Rights Issue. For the top guarantee commitment (top-down, from 100 percent down), which corresponds to approximately 14.5 percent of the Rights Issue, no compensation will be paid. For the second tranche of the top guarantee commitment

[top-down, from 85.5 percent down], which corresponds to approximately 11 percent of the Rights Issue, compensation of 16 percent will be paid in the form of newly issued units, which will be issued on the same terms as the Rights Issue.

In the event that the entire guarantee compensation is paid in the form of shares and subscription options, this will result in the issuance of up to an additional 2,824,200 shares and 2,118,150 subscription options of series TO5, which would correspond to an initial dilution of approximately 7.6 percent and an additional approximately 3.7 percent after the exercise of subscription options of series TO5. The guarantee commitments are not secured through pre-arranged transactions, bank guarantees, or similar to ensure that the funds covered by the commitment will be provided to the Company. See the section 'Risk Factors' under the heading 'Risks related to unsecured subscription commitments and guarantee undertakings.' The parties that have entered into guarantee commitments are listed in the table below.

Guarantor	Org.no.	Address	Bottom guarantee, from pre-subscription level up to 55.5%, [SEK]	Top-down guarantee, level 100.0-85.5%, [SEK]	Top-down guarantee, level 85.5-74.5%, [SEK]	Part of the Offering [%]
Exelity AB	559288-0396	Riddargatan 30, 114 57 Stockholm	5,598,000.00	0	0	20.5
Bäverstenen AB	556155-4543	Ålgatan 6, 973 34 Luleå	0	3,979,292.00	0	14.5
Buntel AB	559373-4295	Ingmar Bergmans Gata 2, 114 34 Stockholm	3,323,000.00	0	0	12.2
Johan Grönholm			0	0	3,000,000.00	11.0
Oliver Molse			2,800,000.00	0	0	10.2
Total			**11,221,000.00**	**3,979,292.00**	**3,000,000.00**	**68.4**

Subscription commitments

The Company has received subscription commitments from the board and other existing shareholders amounting to a total of approximately SEK 3.4 million, corresponding to approximately 12.6 percent of the Rights Issue. The subscription commitments do not entitle to any compensation. The subscription commitments are not secured through pre-arranged transactions, bank guarantees, or similar, which means there is a risk that the commitments, in whole or in part, may not be fulfilled. See the section 'Risk Factors' under the heading 'Risks related to unsecured subscription commitments and guarantee undertakings' for further information. The parties that have entered into subscription commitments are listed in the table below.

Pre-subscriber	Org.no.	Address	Pre-subscription commitment [SEK]	Part of the Offering [%]
Bäverstenen AB	556155-4543	Ålgatan 6, 973 34 Luleå	1,488,880.00	5.4
JDS Invest AB	556739-7996	Östra Ågatan 51a, 753 22 Uppsala	700,000.00	2.6
David Olsson			500,000.00	1.8
La Familia Svensson AB	556848-9735	Sh Bygg, Sten Och Anläggning Ab, Box 417, 751 06 Uppsala	300,000.00	1.1
AJ Lundberg Kapitalförvaltning AB	556969-5223	Disavägen 11, 191 63 Sollentuna	250,000.00	0.9
Michael Häggman			100,000.00	0.4
Jörgen Dahlström			100,000.00	0.4
Total			**3,438,880.00**	**12.6**

ISSUING AGENT

Nordic Issuing AB acts as the issuing institute in connection with the current Rights Issue.

THIS IS A TRANSLATION OF THE ORIGINAL VERSION IN SWEDISH FOR INFORMATION PURPOSES ONLY.
IN CASE OF A DISCREPANCY, THE SWEDISH ORIGINAL WILL PREVAIL.

BOARD OF DIRECTORS AND MANAGEMENT

According to the Articles of Association of Prostatype Genomics, the board shall consist of at least three and at most eight members. Currently, the board of Prostatype Genomics consists of six members. The members of the board are elected until the next annual general meeting.

The board has its registered office in the Municipality of Stockholm. All board members and executive officers can be reached at the Company's address: Augustendalsvägen 20, 131 52 Nacka Strand, where the Company conducts its main operations. The table below presents information about the members of the board, their year of birth, respective positions, the year they were first elected to the board, and whether they can be considered independent in relation to the Company and its management, as well as the Company's major shareholders.

Name	Birth year	Position	Year of entry	Independent in relation to the Company and its management	Independent in relation to larger shareholders
Anders Lundberg	1964	Chairman	2017*	YES	YES
Jörgen Dahlström	1969	Board member	2023	YES	YES
Håkan Englund	1952	Board member	2019	YES	YES
Michael Häggman	1954	Board member	2018	YES	YES
Mattias Prage	1974	Board member	2022	YES	YES

**Board member since 2017, chairman since 2019.*

INFORMATION ABOUT THE BOARD

Anders Lundberg – Chairman of the board since 2019

Anders Lundberg holds a master's degree in mechanical engineering from the Royal Institute of Technology (KTH) in Stockholm. Lundberg is, among other things, the founder and CEO of a telecom equipment supplier recognized in the market, which successfully listed on Nasdaq Stockholm OMX Mid Cap in 2011 (TRMO: Transmode).

Other ongoing assignments

Anders Lundberg is a board member of AJ Lundberg Kapitalförvaltning AB and a deputy board member of Sollentunahem AB and Sollentunafastigheter 2 AB.

Holdings in Prostatype Genomics

Anders Lundberg owns 169,340 shares in the Company through AJ Lundberg Kapitalförvaltning AB.

Jörgen Dahlström – board member since 2023

Jörgen Dahlström holds a PhD in Medical Sciences from Uppsala University. He also has a master's degree in biochemistry from Uppsala University and an Executive Master of Business Administration from MGruppen.

Other ongoing assignments

Jörgen Dahlström is the CEO of Marcodia AB, Mercodia SAS, and Mercodia Inc.

Holdings in Prostatype Genomics

Jörgen Dahlström owns 12,000 shares in the Company.

Håkan Englund – board member since 2019

Håkan Englund has taken several courses in economics and chemistry at Uppsala University, as well as in polymer technology at the Royal Institute of Technology (KTH) in Stockholm. Håkan Englund has more than 30 years of experience in investments and operational

activities within Life Science and healthcare, with a focus on commercialization and business development. He has held several leadership positions within Pharmacia Biotech and Phadia and has developed extensive national and international networks throughout his career. Currently, Englund is the CEO and owner of JDS Invest.

Other ongoing assignments

Håkan Englund is a board member of Antrad Medical AB, Bioservo AB, and Servacq AB, as well as the CEO and owner of JDS Invest AB.

Holdings in Prostatype Genomics

Håkan Englund owns 651,985 shares in the Company through JDS Invest AB and privately.

Michael Häggman – board member since 2018

Michael Häggman is an Associate Professor in the Department of Urology at Uppsala University Hospital. He has over 30 years of experience as a practicing urologist and possesses an extensive national and international network among urologists.

Other ongoing assignments

Michael Häggman is CEO and chairman of the board of Skrotum AB and board member of Kardinaltalet AB.

Holdings in Prostatype Genomics

Michael Häggman owns 57,090 shares in the Company.

Mattias Prage – board member since 2022

Mattias Prage holds a law degree from Uppsala University and is currently a partner and attorney at Lindahl in Uppsala. He has been with Lindahl since 2004 and has extensive experience and specialized expertise in corporate law, capital markets law, commercial agreements, and mergers and acquisitions. Mattias Prage has served as one of Prostatype Genomics' legal advisors since 2019.

Other ongoing assignments

Mattias Prage is a board member of Lindahl i Uppsala Aktiebolag and Uppsala Innovation Centre AB, as well as a board member of Mattias Prage Advokat AB.

Holdings in Prostatype Genomics

Mattias Prage does not own any shares in the Company.

INFORMATION ABOUT MANAGEMENT

All senior executives can be reached at the Company's address, Augustendalsvägen 20, 131 52 Nacka Strand, where the Company conducts its main operations. The table below presents information about the Company's senior executives, including their year of birth, respective positions, and year of appointment.

Name	Birth year	Position	Year of entry
Fredrik Rickman	1966	CEO	2017
Steven Gaal	1969	President US operations	2023
Anders Koch	1973	CFO	2023

Fredrik Rickman – CEO since 2017

Fredrik Rickman holds a Bachelor's degree in Economics from Lund University and has over 30 years of experience in international Life Science, largely in senior positions with a focus on operational and organizational growth.

Other assignments

redrik Rickman is chairman of the board of Stradis Med Nordics AB.

Holdings in Prostatype Genomics

Fredrik Rickman owns 10,007 shares in the Company.

Steven Gaal – CEO of Prostatype Genomics Inc. since 2023

Steven has extensive experience in genomic testing, both in startups and more established companies. Gaal has held senior positions at USLABS (acquired by LabCorp), P4Diagnostix, and most recently SkylineDx. As Head of Sales at MDxHealth, Gaal played a key role in the launch of ConfirmMDx for prostate cancer and SelectMDx for prostate cancer to U.S.-based urologists.

Other assignments

No other assignments.

Holdings in Prostatype Genomics

Steven Gaal does not own any shares in the Company.

Anders Koch – CFO, part time, since 2023

Anders Koch has over 25 years of experience in financial roles and leadership, most recently from an interim assignment at Goodbye Kansas Group AB (publ).

Other assignments

Anders Koch is CEO and board member of Carisus Consulting AB, board member of Carisus Holding AB, and deputy board member of Nogatolp AB.

Holdings in Prostatype Genomics

Anders Koch does not own any shares in the Company.

OTHER INFORMATION ABOUT THE BOARD AND MANAGEMENT

None of the above board members or senior executives have any family relationships with other board members or senior executives.

In the past five years, none of the Company's board members or senior executives have (i) been convicted in fraud-related cases, (ii) been involved in a crime and/or subjected to penalties by a regulatory or supervisory authority (including recognized professional associations), or (iii) been prohibited by a court from being a member of an issuer's administrative, management, or supervisory body, or from holding senior or executive functions at an issuer.

COMPENSATION AND BENEFITS FOR THE BOARD AND MANAGEMENT

The chairman and members of the board receive compensation according to the decision of the annual general meeting. The annual general meeting on May 23, 2024, decided that the annual compensation for non-employee, shareholder-elected board members for 2024 will be SEK 160,000 for the chairman of the board and SEK 80,000 for the other regular board members.

Board members are entitled to compensation for any expenses, transportation, and accommodation related to their board duties. Board members do not have the right to any benefits after their term as board members ends, and the Company has no accrued or reserved amounts for pensions or similar benefits after termination of service. The table below presents compensation and other benefits for the board and senior executives during the most recently audited fiscal year 2024, excluding social security contributions. It is noted that no board compensation has been paid during 2023 or 2024, but has only been accrued.

KSEK	Salary	Board fee	Consultancy fee	Variable compensation	Pension costs	Sum
Board						
Anders Lundberg (ordförande)	-	160	-	-	-	160
Jörgen Dahlström	-	80	-	-	-	80

THIS IS A TRANSLATION OF THE ORIGINAL VERSION IN SWEDISH FOR INFORMATION PURPOSES ONLY.
IN CASE OF A DISCREPANCY, THE SWEDISH ORIGINAL WILL PREVAIL.

Håkan Englund	-	80	-	-	-	80
Michael Häggman	-	80	-	-	-	80
Mattias Prage	-	80	-	-	-	80
Johan Waldhe[1]	-	40	-	-	-	40
Total	**-**	**520**	**-**	**-**	**-**	**520**
Management						
Fredrik Rickman	1,800	-	-	250*	395	2,445
Steven Gaal	2,915	-	-	-	145	3,049
Anders Koch	-	-	2,040	-	-	2,040
Total	**4,704**	**-**	**2,040**	**250**	**540**	**7,531**

[1] *Previous board member of the Company*

** The CEO VD is entitled to a yearly bonus of up to two month's salaries. In the event of resignation by the CEO, the notice period is six months, and in the event of termination by the Company, the notice period is nine months.*

THIS IS A TRANSLATION OF THE ORIGINAL VERSION IN SWEDISH FOR INFORMATION PURPOSES ONLY.
IN CASE OF A DISCREPANCY, THE SWEDISH ORIGINAL WILL PREVAIL.

FINANCIAL INFORMATION AND KEY FIGURES

The historical financial information for Prostatype Genomics has been incorporated into the prospectus by reference. Incorporated documents and cross-references to the respective parts that have been incorporated are presented in the section 'Documents Incorporated by Reference.' The incorporated financial information consists of the Company's audited annual reports for the fiscal years 2023 and 2024. The annual reports have been prepared in accordance with the Annual Accounts Act and the Swedish Financial Reporting Board's general guidelines BFNAR 2012:1 Annual Report and Consolidated Financial Statements (K3). Except for what is expressly stated, no information in the prospectus has been reviewed or audited by the Company's auditor.

The presented historical financial information in this section should be read in conjunction with the incorporated parts of Prostatype Genomics' audited annual reports for the fiscal years 2023 and 2024, which have been incorporated into this prospectus by reference. The parts of the respective financial reports that are not incorporated by reference are deemed not relevant for an investor or contain information that is found in other parts of this prospectus. Reference to the historical financial reports is made as follows:

Prostatype Genomics annual report for the fiscal year 2024, where reference is made as follows: income statement on page 19, balance sheet on pages 20-21, cash flow statement on page 22, statement of changes in equity on pages 23-24, notes on pages 25-36, and the auditor's report on pages 40-42. The annual report has been audited by the Company's auditor. Prostatype Genomics' annual report for the fiscal year 2024 is available at the following link: ***Annual report 2024***

Prostatype Genomics annual report for the fiscal year 2023, where reference is made as follows: income statement on page 23, balance sheet on pages 24-25, cash flow statement on page 26, statement of changes in equity on pages 27-28, notes on pages 29-40, and the auditor's report on pages 44-46. The annual report has been audited by the Company's auditor. Prostatype Genomics' annual report for the fiscal year 2023 is available at the following link: ***Annual report 2023***

Disclosure by the Company's auditor in the auditor's report in the annual report 2024

We draw the attention to the text in the Board of Directors' Report under the section Financing, liquidity and capital needs and disclosure note 2 under the heading Capital needs and going concern, which states that the Company does not have sufcient working capital to fnance operations in 2025, but that the Board of Directors is actively working to solve the capital requirements. If the outcome of this is not as expected,there is signifcant uncertainty about the Company's ability to continue operations. We would also like to draw attention to the text in the Directors' Report under the section Valuation of assets, where it is clear that there is a risk that if the Company's objectives are not achieved within the planned timeframe, it may lead to the intangible assets being amortised at a faster rate, or completely.

Remark from the Company's auditor in the auditor's report in the annual report 2024

On several occasions during the fnancial year, withheld tax, social security contributions and value added tax have not been paid on time. The Board of Directors has thus not fulflled its obligations under the Companies Act, but the omissions have not caused any damage to the Company, apart from interest on late payments.

Disclosure by the Company's auditor in the auditor's report in the annual report 2023

We would like to draw attention to the text in the Administration Report under the section Capital requirement which states that the Company does not have sufficient working capital to finance its operations in 2024, and that the Board of Directors is actively working to solve the need of capital. If the outcome does not meet the Board of Directors' expectations, there is a material uncertainty of the Company's ability to continue its operations. We would also like to draw attention to the text in the section Valuation of assets, where it is stated that there is a risk that if the Company's budgets and forecasts are not achieved within the planned timeframe, it may lead to increased or complete write offs of the intangible assets.

KEY FIGURES

Some of the key figures presented below are not defined according to Prostatype Genomics' applied accounting principles for financial reporting. Prostatype Genomics believes that the key figures provide a better understanding of the Company's financial trends. The key figures, as defined by Prostatype Genomics, should not be compared with the key figures of other companies that use the same terminology, as the definitions may differ. The key figures in the table below have not been audited unless otherwise stated.

THIS IS A TRANSLATION OF THE ORIGINAL VERSION IN SWEDISH FOR INFORMATION PURPOSES ONLY.
IN CASE OF A DISCREPANCY, THE SWEDISH ORIGINAL WILL PREVAIL.

GROUP KSEK	2024-01-01 2024-21-31	2023-01-01 2023-12-31
Net revenue	199	1,356
Total assets	41,970	49,222
Operating result	-40,853	-39,247
Resultat after financial items	-41,051	-41,435
Operating margin	Neg	Neg
Profit margin	Neg	Neg
Return on equity	Neg	Neg
Equity	33,469	24,674
Earnings per share*	-6.12	-346.85
Solidity %	80	50

** comparative figures for earnings per share for the comparison year have been adjusted to reflect the 1,000:1 share consolidation approved at the extraordinary general meeting on October 22, 2024. Earnings per share is not to be considered as an alternative performance measure, in accordance with ESMA's guidelines on alternative performance measures, section V, paragraph 19.*

DEFINITIONS OF ALTERNATIVE KEY FIGURES

Total assets

Total assets or liabilities and equity. The key figure aims to provide investors with an indication of how the Company's assets change over time.

Solidity

Equity divided by total assets. The key figure provides investors with information about the Company's capital structure and how it changes over time.

Operating margin

Operating profit divided by net sales. In case of a negative operating margin, 'Neg' is indicated. The Company considers this key figure relevant as it shows the proportion of sales that remains to cover interest costs, taxes, and generate potential profit.

Profit margin

Profit for the period after financial items divided by net sales. In the case of a negative profit margin, 'Neg' is indicated. The Company considers this key figure relevant as it shows the proportion of sales that results in profit attributable to the Company's shareholders.

Return on equity

Profit for the period after financial items divided by equity. In the case of negative return on equity, 'Neg' is indicated. The Company considers this key figure relevant as it effectively analyzes the profitability generated by the Company's operations in relation to the capital invested and accumulated by the shareholders.

RECONCILIATION OF ALTERNATIVE PERFORMANCE MEASURES, THE GROUP

GROUP KSEK	2024-01-01 2024-12-31	2023-01-01 2023-12-31
Equity	33,469	24,674
Total assets	41,970	49,222
Solidity[1] %	**80**	**50**

[1] Equity divided by total assets

KSEK	2024-01-01 2024-12-31	2023-01-01 2023-12-31
Operating profit	-40,853	-39,247
Net sales	199	1,356
Operating margin[1]	**neg**	**neg**

[1] *Operating profit divided by net sales.*

GROUP KSEK	2024-01-01 2024-12-30	2023-01-01 2023-12-31
Profit for the period after financial items.	-41,051	-41,435
Net sales	199	1,356
Profit margin[1]	**neg**	**neg**

[1] *Profit for the period after financial items divided by net sales.*

GROUP KSEK	2024-01-01 2024-12-31	2023-01-01 2023-12-31
Profit for the period after financial items.	-41 051	-41 435
Equity	33 469	24 674
Return on equity[1]	**neg**	**neg**

[1] *Profit for the period after financial items divided by equity.*

SIGNIFICANT CHANGES IN THE COMPANY'S FINANCIAL POSITION SINCE THE END OF THE MOST RECENT FISCAL PERIOD

The Company has taken out a bridge loan of approximately SEK 5 million in April 2025, in order to finance its operations until the rights issue has been completed. In addition, since December 31, 2024, there have been no significant changes regarding the Company's financial position.

DIVIDEND POLICY

Prostatype Genomics is a growth company where generated profit funds are planned to be allocated to the development of the business. Against this background, the Company does not expect to pay any dividends in the coming years. However, in the future, when the Company's results and financial position allow, dividend payments may become relevant. The Company currently does not have a dividend policy.

THIS IS A TRANSLATION OF THE ORIGINAL VERSION IN SWEDISH FOR INFORMATION PURPOSES ONLY.
IN CASE OF A DISCREPANCY, THE SWEDISH ORIGINAL WILL PREVAIL.

LEGAL MATTERS, OWNERSHIP STRUCTURE, AND ADDITIONAL INFORMATION

SHARES AND SHARECAPITAL

According to the Company's articles of association, adopted at the annual general meeting on May 15, 2025, as of the date of the prospectus, the share capital shall not be less than SEK 2,500,000.00 and shall not exceed SEK 10,000,000.00, divided into a minimum of 25,000,000 shares and a maximum of 100,000,000 shares. As of the date of the prospectus, the Company's registered share capital amounts to SEK 683,521.30, divided into a total of 6,835,213 shares, each with a nominal value of SEK 0.10.

The number of outstanding shares at the beginning of the most recently completed fiscal year was 119,460,007 shares and at the end of the same fiscal year, it was 6,704,770 shares, with the share capital amounting to SEK 670,477.04. After the end of the 2024 fiscal year, a compensation issue of 130,443 shares was registered, increasing the share capital by SEK 13,044.26, after which the number of shares amounted to 6,835,213 and the share capital to SEK 683,521.30. It is noted that an extraordinary general meeting of the Company in October 2024 decided on a share consolidation (1,000:1), which was implemented in the same year. The rights issue will, upon full subscription, initially increase the Company's share capital from SEK 683,521.30 to SEK 3,417,606.50, and the number of shares will increase from 6,835,213 shares to 34,176,065 shares through the new issue of up to 27,340,852 shares.

The shares in the Company are issued in accordance with Swedish law and are denominated in Swedish kronor (SEK). Prostatype Genomics has one class of shares. The Company's shares are listed and traded on Nasdaq First North Growth Market since October 27, 2020. All issued shares are fully paid and freely transferable and have the ISIN code SE0023261532.

OWNERSHIP

As of the date of this prospectus, the number of shareholders in the Company is approximately 2,100. To the knowledge of the Board, there are no shareholder agreements or other arrangements between the Company's shareholders aimed at joint influence over the Company. To the knowledge of the Board, there are also no other agreements or similar arrangements that could lead to a change or prevention of control over the Company.

All shares in the Company have equal voting rights. The table below lists all shareholders holding more than five percent of the capital and votes in the Company as of March 31, 2025, including any known changes thereafter until the date of the prospectus. As of the date of this prospectus, to the Company's knowledge, no physical or legal persons own five percent, or more than five percent, of the total shares or votes in Prostatype Genomics beyond what is stated in the table below. To the best of the Company's knowledge, the Company is not controlled, directly or indirectly, by any shareholder or by different shareholders acting together.

Shareholder	No of shares	Votes and capital
Johan Waldhe[1]	721,213	10.55
Villa Drevan AB / Filip Norlin	699,960	10.24
JDS Invest AB / Håkan Englund[2]	651,985	9.54
Life Science Invest Fund 1 ApS / Dansktysk Ejendomsrådgivning Aps / Jan Poulsen	440,096	6.44
Bäverstenen AB / Hans Öhman	372,220	5.45
Others	*3,949,739*	*57.78*
Total	**6,835,213**	**100.00**

[1] *Previous board member of the Company*
[2] *Board member of the Company*

WARRANT PROGRAMS

Below are the warrant program for Prostatype Genomics. As of December 31, 2024, apart from what is stated below, there are no outstanding warrants, convertible securities, or share-related incentive programs in the Company.

Warrant program 2022/2025A

At the annual general meeting on June 2, 2022, the meeting approved an warrant program, in accordance with good practice, of series 2022/2025A aimed at certain employees and key individuals in the Company and its subsidiaries through a directed issuance of warrants to the Company (with approval for further transfer to the participants in the program). The options program includes a total of 500,000 warrants, which were granted free of charge. All the warrants in the program were subscribed by the Company. Each warrant entitles the holder to subscribe for a new share in the Company at a subscription price of SEK 10. Subscription for shares using the warrants shall occur in accordance with the terms of the warrants from July 1, 2025, until December 31, 2025. Following the Board's recalculation due to completed issuances and the consolidation of shares after the issuance of the options program, each option entitles the holder to subscribe for 0.06 new shares at a subscription price of SEK 171.35, totaling a maximum of 29,180 new shares.

If all the outstanding warrants in the Company are exercised for the subscription of new shares, the Company's registered share capital will increase by SEK 2,918.00 (considering the current nominal value of SEK 0.10 per share and assuming no recalculation is made according to the terms of the warrants). The dilution resulting from the proposed options program, upon full utilization, will amount to 0.43 percent of the shares and votes in the Company, calculated based on the number of outstanding shares in the Company as of the date of this prospectus, excluding the Offering. As of the date of this prospectus, no options have yet been allocated or transferred to any participants.

Warrant program 2025/2029

At the annual general meeting on May 15, 2025, the meeting decided on an warrant program of series 2025/2029 aimed at employees and key individuals in the Company or the Company's group through a directed issuance of warrants to the Company (with approval for further transfer to the participants in the program). The options program includes a maximum of 5,000,000 employee stock options, which will be granted to participants in the program free of charge. Allocation may be made with a total of up to ten percent of the Company's registered number of shares as of September 30, 2025. The total number of employee stock options that can be offered to a participant is a maximum of 50 percent of the allocatable employee stock options. However, if the board considers it commercially justified, the board may decide to deviate from the allocation for one or more participants. Allocation of employee stock options will be decided no later than October 31, 2025. However, allocation may occur earlier or later, based on a specific decision by the board. The granted employee stock options will vest over a period of three years with 1/3 vesting on each anniversary from the date of allocation. Participants may exercise their granted and vested employee stock options during the period from November 1, 2028, to May 1, 2029. Each employee stock option entitles the participant to acquire a new share in the Company during the exercise period at an exercise price corresponding to 125 percent of the volume-weighted average price of the Company's share on Nasdaq First North Stockholm during a period of ten trading days before the annual general meeting on May 15, 2025. The maximum dilution effect of the warrants program is estimated to be approximately ten percent, assuming full exercise of all granted options in the program. The calculation has been made in relation to the number of registered outstanding shares in the Company as of September 30, 2025.

MATERIAL AGREEMENTS

The Company has, apart from what is stated below, not entered into any material agreements in the past year preceding the publication of this prospectus that fall outside the scope of its ordinary course of business.

Bridge financing

The Company has taken out bridge financing loans on two occasions, with agreements dated June 11, 2024, and April 15, 2025. The total amount of the bridge financing is approximately SEK 11.5 million. As of the date of this prospectus, a receivable of SEK 5 million remains, which is intended to be repaid in cash with the proceeds from the Rights Issue or, if the bridge financiers so choose, offset against units as part of the Rights Issue.

Bridge financing dated 11 June 2024

The bridge financing dated June 11, 2024, was agreed upon with Exelity AB (publ) and Buntel AB, totaling approximately SEK 6.5 million, with Exelity AB (publ) contributing around SEK 4.2 million and Buntel AB contributing approximately SEK 2.3 million. The bridge financing agreement was made to ensure the company's liquidity needs until the completion of the rights issue in 2024. As compensation for the bridge financing, a commitment fee of 5% and an interest rate of 2% per 30-day period were charged. The bridge financing was repaid in cash with the proceeds from the rights issue in 2024.

Bridge faincing dated 15 April 2025

The bridge financing dated April 15, 2025, was agreed upon with Exelity AB, Buntel AB, and Oliver Molse, totaling SEK 5 million, with Exelity AB contributing SEK 2.5 million, Buntel AB contributing SEK 1.25 million, and Oliver Molse contributing approximately SEK 1.25 million. The agreement for the bridge financing was made to ensure the Company's capital need until the completion of the rights issue. As compensation for the bridge financing, a commitment fee of 5% was added to the signing fee, and an interest rate of 1.5% per 30-day period will be charged. The bridge financing is intended to be repaid in cash with the proceeds from the rights issue, or, if the bridge financiers so choose, it may be offset against units as part of the rights issue. In case of non-payment, any unpaid portion of the loan will accrue an additional late payment interest of 3.0% from the start of each 30-day period, resulting in a total interest rate of 4.5% in case of non-payment. The bridge loan is to be repaid once the rights issue has been fully registered with the Swedish Companies Registration Office (Bolagsverket). If the payment is not received by June 30, 2025, which is the loan's due date, the payment will be considered missed.

GOVERNMENTAL PROCEEDINGS, LEGAL PROCEEDINGS, AND ARBITRATION PROCEEDINGS

Prostatype Genomics has not been a party to any governmental proceedings, legal proceedings, or arbitration proceedings (including proceedings that have not yet been concluded or that, to the Company's knowledge, may be initiated) during the twelve-month period preceding the date of this prospectus, which may have had or are likely to have a significant impact on the Company's and/or the Group's financial position or profitability, or any indication that such proceedings are not pending.

TRANSACTION WITH RELATED PARTIES

Related parties include all board members, senior executives, and their family members. Below is a description of the transactions with related parties that have been carried out during the period covered by the historical financial information included in the prospectus and the period up to the date of the prospectus.

Shareholder loan from JDS Invest AB

In the second half of 2023, the Company entered into loan agreements of SEK 1.2 million and SEK 2 million with JDS Invest AB, where board member Håkan Englund serves as chairman of the board. The loans were issued under market terms. The SEK 1.2 million loan was converted into shares in the Company during the preferential rights issue that concluded on January 6, 2024, while the SEK 2 million loan accrued interest at a rate of 12%. JDS Invest AB received a total of SEK 57,000 in interest for the loans during 2023. In 2024, an additional loan of SEK 2 million was taken from JDS Invest AB, which accrued interest at a rate of 10%. Furthermore, SEK 800,000 of the previous loan was offset as payment for the redemption of series TO 3 warrants in April 2024. All remaining loan financing from JDS Invest AB after April 2024 (totalling SEK 3.2 million) was converted into shares during the preferential rights issue the Company carried out in the fall of 2024.

Guarantee compensation

In the preferential rights issue conducted by the Company in April/May 2023, JDS Invest AB (wholly owned by board member Håkan Englund) acted as a guarantor and thereby received compensation of SEK 60,000. Additionally, Johan Waldhe (formerly a board member) also acted as a guarantor, for which Waldhe received a cash compensation of SEK 120,000. At that time, Waldhe was no longer a board member of the Company.

Consultancy fees

The Company procures web-based solutions for P-score from SecureAppbox AB, where Håkan Englund was the chairman of the board until 2024. In 2023 and 2024, services worth SEK 396,000 and SEK 630,000, respectively, were purchased. Board member Håkan Englund was not involved in the procurement of these services. Håkan is no longer a board member of SecureAppbox AB.

Board member Mattias Prage is employed at Lindahl, which the Company hires for legal advisory and corporate administration services. In 2023 and 2024, Lindahl invoiced the Company SEK 1,321,000 and SEK 1,036,000, respectively. Board member Mattias Prage was not involved in the procurement of these services.

Johan Waldhe, a former board member, owns the PR and consultancy firm Honeybadger AB. In 2023 and 2024, Honeybadger AB invoiced the Company SEK 130,000 and SEK 1,844,000, respectively. The services were procured on market-based terms.

CONFLICTS OF INTEREST

A number of board members of Prostatype Genomics own shares and warrants in the Company. Shareholdings for each person are presented in more detail under the section “Board of Directors and senior executives” in this prospectus. Prostatype Genomics has also entered into agreements on subscription commitments and guarantee undertakings with a number of board members, existing shareholders and external investors. Subscription commitments and guarantee undertakings given are described in more detail in the section “Terms and conditions” in this prospectus. In addition, board member Mattias Prage is also a partner in and a lawyer at Lindahl.

There is no conflict of interest within the administrative, management and supervisory bodies or with other persons in senior positions in Prostatype Genomics, nor are there any other natural or legal persons involved in the issue who have financial or other relevant interests in the Company.

THIS IS A TRANSLATION OF THE ORIGINAL VERSION IN SWEDISH FOR INFORMATION PURPOSES ONLY.
IN CASE OF A DISCREPANCY, THE SWEDISH ORIGINAL WILL PREVAIL.

AVAILABLE DOCUMENTS

Copies of Prostatype Genomics articles of association, memorandum of association, registration certificate and full terms and conditions for warrants of series TO5 are available at Prostatype Genomics' head office, Augustendalsvägen 20, 131 52 Nacka Strand, during the validity period of the prospectus [ordinary business hours]. The documents are also available in electronic form on the Company's website www.prostatypegenomics.com. Please note that the information on the website does not form part of the prospectus and has not been reviewed or approved by the Swedish Financial Supervisory Authority.